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Abstract 
Natural products display a rich source of bioactive molecules and have traditionally 
contributed to the identification and investigation of potential targets for drug development. 
Especially in devastating diseases such as cancer novel targets are urgently needed in 
order to exploit disease related pathways and to develop respective targeted therapies. 
Inspired by the promising anticancer activities of the myxobacterial compound 
Vioprolide A (VioA) and the marine cyanobacterial product Lagunamide A (LagA), we 
performed in depth studies on their modes of action. 
The Vioprolides represent a unique class of natural products with potent bioactivity 
towards cancer cells in the nanomolar range. By applying thermal proteome profiling 
(TPP) in cooperation with the group of Prof. Dr. Stephan Sieber (TU Munich, Germany), 
we could identify the nucleolar protein 14 (NOP14), as direct interaction partner of VioA, 
the most potent growth inhibitory Vioprolide derivative. NOP14 is involved in ribosome 
biogenesis and plays a key role in the assembly of the ribosomal subunit. In fact, VioA 
represents the first small molecule addressing this crucial pathway. Peripheral blood 
mononuclear cells (PBMCs) of healthy donors showed a low response to VioA in contrast 
to acute lymphoblastic leukemia (ALL) cells, highlighting VioA as promising lead structure 
for cancer cell targeting. Furthermore, closer mechanistic studies revealed that VioA 
impairs the interaction between NOP14 and the essential ribosome assembly factor 
ribosomal RNA small subunit methyltransferase Nep1 (EMG1). Concluding, our results 
indicate that targeting ribosome biosynthesis is a promising anticancer strategy and 
underscores the great potential of VioA as chemical tool to study ribosome assembly 
processes as well as starting point for future drug development. 
 
Fig. 1 The Vioprolide A project at a glance. 
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Besides the ribosome biogenesis machinery, mitochondria have emerged as potential 
anticancer targets in recent years, as cancer cell mitochondria are structurally and 
functionally different from their non-cancerous counterparts. Detailed functional 
characterization of the marine natural compound LagA suggests a mitochondria-
perturbing mode of action, comprising changes in mitochondrial dynamics and resulting in 
mitochondrial apoptotic cell death. These findings emphasize the need to elucidate the 
molecular targets addressed by this interesting molecule, which is not known yet. LagA 
represents a promising new compound with potentially important applications as both 
anticancer drug lead structure and molecular probe to explore cancer-related 
mitochondrial pathways. 
 
Fig. 2 The Lagunamide A project at a glance. 
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1. Introduction 
1.1 Natural compounds- a source for innovation in cancer 
research 
1.1.1 Natural products - model molecules for the discovery of new drug 
targets 
Naturally occurring compounds display an exceptional diversity of bioactive molecules 
with interesting biological activities, making them an essential source of both drug leads 
and cell biology tools. Their importance is further illustrated by the fact that approximately 
50% of all FDA approved anticancer drugs since the 1940s are natural products or 
derivatives of them (1). But, particularly cancer therapy still suffers from a restricted 
spectrum of molecular targets that can be addressed by small molecules, albeit the 
introduction of targeted chemotherapy significantly improved treatment results and 
revolutionized cancer therapy in the recent decades (2). However, drug resistance, 
therapeutic failure or relapse are still widespread and require identification and validation 
of novel and innovative drug targets optimized for specific cancer relevant proteins and 
pathways. In this context, natural products are particularly valuable as research tools, 
because they are often coevolved with protein targets and, therefore, are prone to exhibit 
high selectivity for a wide variety of biological targets for specific purposes (3). 
Identification of the molecular targets of newly discovered natural compounds has had 
insightful effects on studies of complex cellular machineries, demonstrating the role of 
specific targets and pathways. Consequently, despite the technical hitches implicated in 
isolating and synthesizing natural products, successful identification of their targets 
stimulates research in basic cell biology and biomedicine (4).  
1.1.2 Myxobacteria and marine cyanobacteria- prolific sources for lead 
structures 
One example of a fruitful source for new natural compounds with high chemical diversity, 
biochemical specifity and unusual modes of actions are myxobacteria (5). The gram-
negative myxobacteria are unicellular rod shaped bacteria that occur in soil, dung of 
herbivorous animals or decaying plant material (6). They are characterized by an unusual 
way of life, as they move by gliding on surfaces and have the ability to form ‘social’ 
multicellular fruiting bodies when nutrients become limited (7). Myxobacteria have one of 
the largest bacterial genomes and one more remarkable characteristic is that they are 
amongst the top producers of a wide range of secondary metabolites with unique 
structural properties (5, 8). Interestingly, these products often have unusual target 
structures, which are rarely or not targeted by other metabolites, making them excellent 
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tools for the identification of novel targets and cellular pathways (9). In 2007, Ixabepilone, 
an analogue of the myxobacterial molecule Epothilone B, was FDA approved for the 
treatment of metastatic breast cancer (10), signifying that myxobacterial compounds also 
display a considerable resource for the development of new lead structures in drug discovery 
processes. 
Besides natural compounds from terrestrial plants or microbes that have long been the 
traditional source of lead structures, the isolation of marine natural products from various 
organisms led to great success in anticancer drug discovery in recent years (11, 12). Their 
significance is highlighted by the fact that four marine organism-derived compounds are 
currently in clinical use for the treatment of cancer: cytarabine (Cytosar®), Trabectidin 
(Yondelis®), Eribulin (Halaven®) and the conjugated antibody Brentuximab vedotin 
(Adcetris®) (11). The small molecule part of Brentuximab vedotin, monomethyl auristatin 
E is designed based on the marine cyanobacterial molecule Dolastatin 10 (13). Amongst 
other marine microbes, cyanobacteria represent an exceptionally rich source of 
structurally diverse molecules with promising pharmacological activities. The prokaryotic 
cyanobacteria, also known as blue-green algae, exist as unicellular species or in colonies 
and are able to obtain energy through photosynthesis (14). As cyanobacteria are an 
ancient group of organisms, they produce compounds that are optimized by evolution over 
billions of years to efficiently target relevant pathways, highlighting the perception that 
marine cyanobacteria-derived molecules hold great promise in developing biochemical 
study tools and agents for cancer (15).  
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1.1.3 Vioprolides 
From the myxobacterial strain Cystobacter violaceus, Schummer et al. reported the 
isolation of the four novel metabolites Vioprolide A-D (16). The cyclic structure of this 
natural compound family is composed of eight amino acids and one glyceric acid (Figure 
1). In this initial publication from 1996, the vioprolides were described to exert striking 
antifungal and anticancer activities, encouraging further biological analyses of this 
interesting class of compounds. Recently, Vioprolide A has been described to be a potent 
activator of IL-1ß maturation and to induce intrinsic apoptosis in primary murine 
macrophages (17). Moreover, detailed studies on the biosynthesis of vioprolides have 
been performed lately (18, 19). But, despite their promising biological activity, no 
molecular target and mode of action elucidation was reported up to date.  
 
Fig.3 Chemical structures of Vioprolides A-D. Structural differences in N-heterocycles are 
highlighted. 
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1.1.4 Lagunamides 
Lagunamide A and its analogues Lagunamides B and C are potent cyclic depsipeptides 
obtained from the marine cyanobacterium, Lyngbya majuscula. These molecules are 
structurally related to a series of other cytotoxic marine cyanobacterial compounds like the 
Aurilides or Kulokekahilide-2, which are already known to exhibit striking anticancer 
effects (20). Previous studies also described potent growth inhibitory activities in the low 
nanomolar range against a panel of cancer cell lines (21). Furthermore, first biochemical 
studies of Lagunamide A revealed that the cytotoxic effect of the natural compound is 
triggered via mitochondria-mediated apoptosis (22). Still, in depth studies concerning the 
mechanism of action upstream intrinsic apoptosis induction are not available.  
 
Fig. 4 Chemical structure of Lagunamide A. Lagunamide A was first isolated from the marine 
cyanobacterium Lyngbya majuscula obtained from Pulau Hantu Besar, Singapore. Figure adapted 
from Tripathi et al. (21), permission to reuse figure was obtained. 
 
1.2 The nucleolus- an emerging target for cancer therapy 
1.2.1 The nucleolus as the main site for ribosome biogenesis 
The nucleolus is a dynamic, sub-nuclear and membrane-less organelle, first described in 
the 1830s by the German physiologists Rudolph Wagner and Gabriel Valentin (23, 24). In 
the early 1960s the discovery was made that the nucleolus is the site of ribosomal RNA 
(rRNA) synthesis and nascent ribosome assembly (25). It is now apparent that 
arrangement of nucleoli depends on ongoing transcription of ribosomal DNA (rDNA), 
where 18S, 28S, and 5.8S rRNAs are encoded. Perturbations that lead to inhibition of 
rRNA synthesis rapidly result in disassembly of nucleoli (26). Consistently, the nucleolus 
disassembles during the onset of mitosis, when rDNA transcription is halted and 
reassembles during the early G1 phase (27). Genes that encode for rRNA are arranged in 
the nucleoli as arrays of head-to-tail tandem repeats, termed nucleolar organizer regions 
(NOR). In detail, the 47S rRNA precursor that is transcribed by RNA polymerase I (Pol I) 
in the nucleolus, is further processed in order to generate the mature 18S, 5.8S and 28S 
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rRNA. The 5S rRNA transcribed by RNA polymerase III (Pol III) in the nucleoplasm, is 
imported to the nucleolus (28). The mature rRNAs represent the nucleic acid backbone of 
the ribosome and finally assemble with the numerous ribosomal proteins, whose mRNA is 
transcribed by RNA polymerase II (Pol II) to form the small pre-40S and the large pre-60S 
ribosomal subunits. Subsequently the mature ribosomal subunits interact with the export 
machinery and migrate to the cytoplasm, where they finally make up the mature 80S 
ribosome particle (26). In summary, ribosome biogenesis is one of the most complex and 
energy consuming processes of a cell that needs the coordinated activity of all three RNA 
polymerases and many transiently associated ribosome assembly factors. Biogenesis of 
ribosomes is furthermore tightly regulated and linked to other fundamental cellular 
processes, like cell growth and division (29).  
 
Fig. 5 Overview of ribosome biogenesis. Ribosome biogenesis mainly takes place in the 
nucleoli, where RNA polymerase I (Pol I) transcribes 47S pre-rRNAs from ribosomal DNA (rDNA) 
genes. The 47S precursor rRNA is further processed to 18S, 5.8S and 28S rRNAs. Together with 
the 5S rRNA transcribed by RNA polymerase III (Pol III) and ribosomal proteins (RPs) the rRNAs 
are assembled to the 90S processome. During the maturation of the 90S processome into pre-
40S and pre-60S ribosomal subunits, pre-rRNA is modified and processed through mechanisms 
that involve small nucleolar RNAs (snoRNAs). The 40S subunit contains 18S ribosomal RNA 
(rRNA) and 33 RPs, the 60S subunit contains 5S, 5.8S and 28S rRNAs and 47 RPs. The 
subunits get transported to the cytoplasm, where they finally assemble to mature 80S ribosomes.  
Adapted from Pelletier et al. (30), permission to reuse figure was obtained. 
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1.2.2 Ribosome biogenesis in cancer 
Cancer cells exhibit a number of abnormal properties in order to maintain their 
uncontrolled growth and proliferation. In this context ribosome biogenesis and protein 
synthesis are essential cellular processes necessary for persistent cancer cell growth 
(31). The transient nucleolus thereby plays a fundamental role in the up-regulated 
synthesis of rRNA to maintain ribosome biogenesis, which is considered a hallmark of 
cancer. Obviously, cell growth depends on protein production and is therefore coupled to 
the synthesis of rRNA by Pol I and Pol III. Thus, an activated Pol-I-specific oncogenic 
transcription factor can be enough to accelerate proliferation (32). Hypertrophy of the 
nucleolus, which can be visualized by analysis of silver- stained nucleolar organizer 
regions (AgNOR) is one of the most characteristic cytological features of cancer cells and 
the earliest link between the nucleolus and malignant transformation (26, 33). In detail, it 
is the dense concentration of macromolecules at the sites of rRNA synthesis that is 
responsible for the strong visibility of nucleoli that withdraw if transcription is deficient. 
Conversely, nucleoli expand when Pol I transcription is elevated. The inflated nucleoli of 
cancer cells are therefore an obvious indication that rRNA synthesis is unusually high 
(32). Ribosome biogenesis is carefully controlled by multiple cell signaling pathways that 
converge on the Pol I complex. Because rRNA synthesis is the rate-limiting step of 
ribosome biogenesis, many Pol I regulators play critical roles in cancer (34). Oncogenic 
signaling, for example activation of MYC or ERK signalling pathways can up-regulate Pol I 
to accelerate ribosome biogenesis, whereas tumor suppressor proteins like p53 can inhibit 
rRNA synthesis (32, 35).  
Concluding, there is an obvious contribution of the nucleolus to malignant transformation, 
highlighting its potential as a target for cancer therapy and the necessity to develop 
respective targeted therapies. 
 
1.2.3 The nucleolus as a drug target 
The great potential of targeting the nucleolus and thereby ribosome biogenesis in cancer 
is gaining more and more interest, not least because many drugs currently used for 
cancer therapy have been shown to exert their cytotoxic activity at least in part by 
inhibition of rRNA synthesis (36). More precisely, drugs that either damage DNA or hinder 
DNA synthesis, like Cisplatin, Oxaliplatin, Doxorubicin or Mitoxantrone inhibit ribosome 
biogenesis at the level of Pol I transcription, resulting in nucleolar disruption (26). 
Moreover, drugs like 5-Fluorouracil and the translation inhibitor Homoharringtonine impair 
late rRNA processing (37). However, none of these examples is selective enough for Pol I 
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transcriptional inhibition to allow precise conclusions how ribosome biogenesis inhibition 
contributes to therapeutic success. Conversely, a new generation of drugs that selectively 
inhibit Pol I transcription is currently in development (35). A major advantage thereby is 
that Pol I specific inhibitors, in contrast to DNA damaging agents, only hinder ribosome 
biogenesis without being genotoxic (36). The first agent targeting Pol I transcription is 
CX-3543, which binds G-quadruplex DNA structures in rDNA repeats and prevents 
nucleolin/ G-quadruplex complex formation (38). In that way, it acts quite similar to 
Actinomycin D, which intercalates into GC- rich duplex DNA that is common in rDNA 
repeats (37). The small molecule CX-5461 presents the next generation of Pol I inhibitors 
that impair transcription by disrupting the binding of the transcription initiation factor SL-1 
to the rDNA promoter. With a remarkable selectivity towards Pol I that is 300-400 fold 
higher than to Pol II or Pol III, CX-5461 has shown to be effective in a wide range of 
human cancer cell lines at low nanomolar concentrations and currently in phase I/ II 
clinical trials (39, 40).  
Summarizing, the introduction of these novel specific rRNA synthesis inhibitors may 
stimulate more studies aiming to identify compounds that selectively target the nucleolus 
and the ribosome biogenesis machinery in cancer cells. 
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1.3 Mitochondria as anticancer drug target 
1.3.1 Mitochondrial processes in cancer 
Mitochondria are double membrane-enclosed organelles that have been integrated into 
modern eukaryotes via symbiosis of a proteobacterium 1.5-2 billion years ago (41). Due to 
their versatile roles in ATP production, generation of reactive oxygen species (ROS) and 
regulation of apoptosis; mitochondria are involved in various pathological processes, like 
neurodegenerative diseases, aging, diabetes and cancer. Furthermore these multifaceted 
functions of mitochondria make them important cellular stress sensors in normal 
physiology. But on the other hand mitochondria also provide flexibility for tumor cell 
growth and survival in harsh conditions, such as starvation, hypoxia and anti-cancer 
treatments, signifying that mitochondria are key players in tumorigenesis (42). Non-
malignant cells mainly rely on oxidative phosphorylation for ATP production, whereas 
cancer cells exhibit enhanced glycolysis, despite the presence of oxygen (43). This 
phenomenon is known as the Warburg effect. Importantly, ATP production by aerobic 
glycolysis, which directly results in increased generation of lactate, is advantageous to 
cancer cells because it allows them to better survive under conditions of varying oxygen 
levels (44). 
1.3.2 The mitochondrial cell death machinery 
In addition to their essential role in energy metabolism, mitochondria are the central 
mediators of intrinsic apoptosis. Thereby, the pro-apoptotic Bcl-2 family members BAX 
and BAK are recruited to the outer mitochondrial membrane (OMM) and oligomerize to 
mediate mitochondrial outer membrane permeabilization (MOMP), resulting in 
cytochrome C release from the mitochondrial intermembrane space. Released to the 
cytosol, cytochrome C activates downstream caspases to execute programmed cell 
death. Under normal physiological conditions, anti-apoptotic family members such as 
Bcl-2 and Bcl-xL bind and inhibit BAX/BAK. A hallmark of cancer is resistance to 
apoptosis by downregulating pro-apoptotic and upregulating anti-apoptotic proteins, which 
is also contributing to chemoresistance (45).  Besides the permeabilization of 
mitochondria that is mediated by Bcl-2 family members, mitochondrial apoptosis is also 
accompanied by morphological changes, the so called cristae remodeling. These 
ultrastructural changes are required to enable the complete release of cytochrome C from 
the cristae space to the intermembrane space, where it can be released across the outer 
mitochondrial membrane (46). A key player in mitochondrial cristae remodeling is the 
dynamin-like GTPase optic atrophy 1 (OPA1) that functions as glue holding the cristae 
together (47). Ongoing apoptosis leads to reduction of mitochondrial membrane potential, 
activating the protease OMA1, which in turn can cleave OPA1. Cleavage of OPA1 results 
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in disassembly of cristae junctions and allows complete release of cytochrome C. 
Remarkably, enforced expression or oligomerization of OPA1 can delay apoptosis, 
substantiating that cristae remodeling plays a crucial role in the control of cell death (48). 
Taken together, the mitochondrial apoptotic machinery provides multiple target structures 
that can be potentially used for chemotherapeutic intervention. 
1.3.3 Mitochondrial dynamics in cancer 
There are more aspects of mitochondrial biology beyond bioenergetics and regulation of 
cell death that support malignant transformation and therefore provide a basis for 
anticancer therapy: the mitochondrial fission and fusion dynamics. Mitochondria are 
extremely dynamic organelles that either exist as fused tubular networks or fragmented 
granules (49). This balance of fission and fusion is regulated by multiple parameters like 
mitochondrial metabolism, respiration, oxidative stress or cellular state (50). Altered 
mitochondrial dynamics is a key feature of cancer. Multiple studies revealed an imbalance 
of fission and fusion in cancer with elevated fission activity and/ or decreased fusion 
resulting in a fragmented mitochondrial phenotype (51). This observation is particularly 
striking in KRAS dependent tumours, where oncogenic KRAS signaling stimulates 
mitochondrial division via ERK-mediated phosphorylation of DRP1- a key player in 
mitochondrial membrane fission (52). Importantly, restoration of mitochondrial fusion by 
DRP1 inhibition or overexpression of the mitochondrial fusion regulator Mfn-2 impaired 
cancer cell growth, signifying that mitochondrial network remodeling plays a crucial role in 
tumorigenesis (51, 52). However, the oncogenic transcription factor c-MYC also 
influences mitochondrial dynamics mainly resulting in mitochondrial fusion (53). These 
findings demonstrate that there are diverging effects of oncogenic signaling on 
mitochondrial dynamics and further investigations are needed to understand these 
correlations in the context of cancer. 
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1.4 Aim of the study 
With Lagunamide A from marine cyanobacteria and the myxobacterial Vioprolide A we 
have two interesting natural products in hands that already have been shown to exert 
striking activity against cancer cells. First biological data leave no doubt that both natural 
products are promising candidates for new anticancer drug leads. However, detailed 
characterization of the respective modes of action of these potent molecules is still 
missing. For that reason, we aimed to explore the anticancer properties of Vioprolide A 
and Lagunamide A in depth and to elucidate their mechanisms of action in order to reveal 
their potential as future anticancer drug leads as well as molecular probes. 
Part I: Vioprolide A  
Direct target and mode of action elucidation 
1. Functional characterization in tumor cells concerning proliferation, migration and 
apoptosis 
2. Target identification via thermal protein profiling (TPP) performed by Volker Kirsch 
(Group of Prof. Sieber, TU Munich) 
3. Target verification and revelation of its role in cancer cells 
4. Mechanistic studies on drug - target interactions 
 
Part II: Lagunamide A  
Mode of action studies with focus on mitochondrial pathways 
1. Functional characterization in tumor cells concerning proliferation, migration and 
apoptosis 
2. Analysis of mitochondrial dynamics and morphology 
3. Studies on mitochondrial function (oxygen consumption, ATP production) 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Cells 
2.1.1.1 Cell lines 
Table 1 List of cell lines 
Cell line Supplier 
BxPC3 ATCC, Manassas, VA, USA 
CCRF-CEM M. Kavallaris, Sydney, Australia 
Hela DSMZ, Braunschweig, Germany 
HL-60 ATCC, Manassas, VA, USA 
S-Jurkat  P.H. Krammer, Heidelberg, Germany 
Jurkat neo P.H. Krammer, Heidelberg, Germany 
Jurkat Bcl-2 P.H. Krammer, Heidelberg, Germany 
Jurkat Bcl-xL P.H. Krammer, Heidelberg, Germany 
Jurkat CASP8 -/- P.H. Krammer, Heidelberg, Germany 
Panc 03.27 ATCC, Manassas, VA, USA 
Panc 10.05 ATCC, Manassas, VA, USA 
T24 DSMZ, Braunschweig, Germany 
 
2.1.1.2 Patient derived xenograft cells 
Patient derived xenograft (PDX) cells were kindly provided by the group of Prof. Dr. Irmela 
Jeremias (Helmholtz Center, Munich, Germany) after isolation from the bone marrow or 
spleen of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. PDX cells were cultured in 
RPMI 1640 containing 20% FCS, 1mM pyruvate and P/S. The technique of growing 
patient leukemia cells in mice has been described previously (54, 55). Patients’ clinical 
characteristics are summarized in Table 2. Written informed consent was obtained from all 
patients. The study was performed in accordance with the ethical standards of the 
responsible committee on human experimentation (written approval by the Research 
Ethics Boards of the medical faculty of Ludwig-Maximilians-University, Munich, numbers 
068-08 and 222-10) and with the Helsinki Declaration of 1975, as revised in 2000. 
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Table 2 Clinical characteristics of patient derived xenograft (PDX) cells. ALL: Acute 
lymphoblastic leukemia. 
Sample Disease stage Age Sex Subtype Karyotype 
ALL-50 initial diagnosis 7 female pre-B t(1;19) 
ALL-199 relapse 2 8 female pre-B somatic trisomy 21 
ALL-707 initial diagnosis 2 male pro-B t(4;11) 
 
2.1.1.3 Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated from blood of healthy donors by 
gradient centrifugation. Isolation was performed by Fabian Koczian in the laboratory of 
Prof. Dr. Angelika Vollmar as described previously (56). 
2.1.2 Compounds 
Vioprolides A-D were kindly provided by Prof. Dr. Rolf Müller (Helmholtz Centre for 
Infection Research, Saarbrücken, Germany). Lagunamide A was kindly provided by Prof. 
Dr. Uli Kazmaier (Institute for Organic Chemistry, Saarland University, Saarbrücken, 
Germany). The study compounds were dissolved in sterile DMSO for cell culture and 
aliquoted for long-term storage at -20°C. 
Actinomycin D (ActD) was dissolved in DMSO and purchased from Sigma Aldrich 
(St Louis, MO, USA). 
2.1.3 Antibodies 
Table 3 List of primary antibodies 
Primary Antibody Source Supplier 
Actin  Mouse Millipore, Darmstadt, Germany 
Bcl-2 Rabbit Cell Signaling, Danvers, MA, USA 
Bcl-xL Rabbit Cell Signaling, Danvers, MA, USA 
BrdU  Mouse Sigma Aldrich, St. Louis, MO, USA 
Caspase-3 Rabbit Santa Cruz, Dallas, TX, USA 
Caspase-8 Mouse Cell Signaling, Danvers, MA, USA 
Cytochrome c Rabbit Cell Signaling, Danvers, MA, USA 
DRP1 Rabbit Cell Signaling, Danvers, MA, USA 
Phospho-DRP1 (Ser616) Rabbit Cell Signaling, Danvers, MA, USA 
Phospho-DRP1 (Ser637) Rabbit Cell Signaling, Danvers, MA, USA 
EMG1 Mouse Sigma Aldrich, St. Louis, MO, USA 
Mcl-1 Rabbit Cell Signaling, Danvers, MA, USA 
NOP14 Rabbit Sigma Aldrich, St. Louis, MO, USA 
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NOC4L Rabbit Sigma Aldrich, St. Louis, MO, USA 
PARP Rabbit Cell Signaling, Danvers, MA, USA 
PGC1α Rabbit Abcam, Cambridge, UK 
PHB1 Rabbit Cell Signaling, Danvers, MA, USA 
 
Table 4 List of secondary antibodies 
Secondary antibody Source Supplier 
Anti-rabbit IgG, HRP  Goat Dianova, Hamburg, Germany 
Anti-mouse IgG1, HRP Goat Abcam, Cambridge, UK 
Alexa Fluor 488, anti-mouse IgG (H+L) Goat Thermo Fisher, Waltham, MA, 
USA 
Alexa Fluor 488, anti-rabbit IgG (H+L) Goat Thermo Fisher, Waltham, MA, 
USA 
Alexa Fluor 647, anti-rabbit IgG (H+L) Chicken Thermo Fisher, Waltham, MA, 
USA 
 
2.1.4 Small interfering RNA 
For gene silencing, ON-TARGETplus SMARTpool small interfering RNA (siRNA) reagent 
from GE Dharmacon (Lafayette, CO, USA) against human NOP14 was used. ON-
TARGETplus non-targeting control siRNA served as control for RNA interference 
experiments. SiRNAs were resuspended in 1x siRNA buffer (diluted from Dharmacon 5x 
siRNA buffer in RNAse-free water) according to Dharmacon siRNA resuspension protocol 
to a final concentration of 20µM, aliquoted and stored at -20°C. 
2.1.5 Chemicals and reagents 
Table 5 List of biochemicals, kits, dyes and cell culture reagents 
Reagent Supplier 
5x siRNA buffer Dharmacon, Lafayette, CO, USA 
2,2,2-Trichloroethanol (TCE) Sigma Aldrich, St. Louis, MO, USA 
µMACS™ Protein G Micro Beads  Miltenyi Biotech, Bergisch Gladbach, 
Germany 
Active Ras Detection Kit Cell Signaling, Danvers, MA, USA 
Ammonium persulfate (APS) Sigma Aldrich, St. Louis, MO, USA 
Bovine serum albumin (BSA) Sigma Aldrich, St. Louis, MO, USA 
Bradford reagent Roti®Quant Bio-Rad, Munich, Germany 
Cell-Titer Blue® (CTB) Promega, Madison, WI, USA 
Collagen G Biochrom AG, Berlin, Germany 
Complete® Roche Diagnostics, Basel, Switzerland 
Coumaric acid Fluka, Buchs, Switzerland 
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CyQuant® Cell Proliferation Assay Kit Life Technologies, Eugene, USA 
Dharmafect 1 Reagent Dharmacon, Lafayette, CO, USA 
DMEM cell culture medium PAN Biotech, Aidenbach, Germany 
Dimethylsulfoxide (DMSO) AppliChem, Darmstadt, Germany 
Fetal calf serum (FCS) PAN Biotech, Aidenbach, Germany 
FluorSave® Reagent Merck, Darmstadt, Germany 
FuGene HD Promega, Madison, WI, USA 
Glutaraldehyde 2,5% in 0.1M Sodium 
Cacodylate Buffer, pH 7.4 
EMS Science Services, Hatfield, PA, USA 
Glycerol Applichem, Darmstadt, Germany 
High-Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, Foster City, CA, USA 
Hoechst 33342 Sigma Aldrich, St. Louis, MO, USA 
Human recombinant insulin Sigma Aldrich, St. Louis, MO, USA 
IMDM Thermo Fisher, Waltham, MA, USA 
JC-1 Enzo, Farmingdale, NY, USA 
Luminol AppliChem, Darmstadt, Germany 
Matrigel™ Corning Incorporated, New York, NY, USA 
MicroAmp® Fast Optical 96-Well 
Reaction Plate 
Applied Biosystems, Waltham, USA 
MitoTracker Green FM Molecular Probes, Darmstadt, Germany 
MitoTracker Deep Red FM Molecular Probes, Darmstadt, Germany 
Na₂EDTA x 2H₂O Sigma Aldrich, St. Louis, MO, USA 
Na₃VO₄ ICN Biomedicals, Aurora, OH, USA 
Nonfat powdered milk (Blotto) Carl Roth, Karlsruhe, Germany 
Page-Ruler™ Prestained Protein Ladder Thermo Fisher, Waltham, MA, USA 
Penicillin/Streptomycin PAN Biotech, Aidenbach, Germany 
PMSF Sigma Aldrich, St. Louis, MO, USA 
Rotiphorese Gel 30 Carl Roth, Karlsruhe, Germany 
PowerUp™ SYBR® Green Master Mix Applied Biosystems, Waltham, MA, USA 
Propidium iodide Sigma Aldrich, St. Louis, MO, USA 
Pyronin Y Sigma Aldrich, St. Louis, MO, USA 
Pyruvate Merck, Darmstadt, Germany 
Qiagen RNeasy Mini Kit Qiagen, Hilden, Germany 
RPMI 1640 cell culture medium PAN Biotech, Aidenbach, Germany 
Seahorse XF Base Medium Agilent Technologies, Santa Clara, CA, USA 
Seahorse XF MitoStress Test Kit Agilent Technologies, Santa Clara, CA, USA 
Seahorse XFe96 FluxPaks Agilent Technologies, Santa Clara, CA, USA 
Sodium dodecyl sulfate (SDS) AppliChem, Darmstadt, Germany 
TEMED VWR, Radnor, PA, USA 
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Tris Base Sigma Aldrich, St. Louis, MO, USA 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween 20 VWR, Radnor, PA, USA 
 
All commonly used acids, bases, buffer salts and organic solvents were either purchased 
from Merck (Darmstadt, Germany) or Sigma Aldrich (St Louis, MO, USA). 
2.1.6 Technical equipment 
Table 6 Technical equipment 
Device Producer 
µMACS™ separator Miltenyi Biotech, Bergisch Gladbach, Germany 
µColumns  Miltenyi Biotech, Bergisch Gladbach, Germany 
Axiovert 25/200 microscope  Zeiss, Oberkochen, Germany 
BEEM® capsule G360.1 Plano GmbH, Wetzlar, Germany 
Bold Line incubation system  Okolab, Pozzuoli, Italy 
ChemiDoc Touch Imaging System Bio-Rad, Hercules, CA, USA 
Cell culture flasks, tubes and plates VWR, Bruchsal, Germany 
CIM plate 16 ACEA Biosciences, San Diego, CA, USA 
E plate 16 ACEA Biosciences, San Diego, CA, USA 
EOS 450C camera Canon, Tokyo, Japan 
FACS Canto II BD, Franklin Lakes, NJ, USA 
HeraCell incubator Heraeus, Hanau, Germany 
ibiTreat µ-slide 8-well ibidi GmbH, Munich, Germany 
Leica DMi1 microscope Leica Microsystems, Wetzlar, Germany 
Leica-SP8 confocal microscope Leica Microsystems, Wetzlar, Germany 
Mini PROTEAN 3 chamber Bio-Rad, Hercules, CA, USA 
NanoDrop® ND-100 Spectrophotometer Peqlab Biotechnology, Erlangen, Germany 
Nitrocellulose membrane Amersham Bioscience, Freiburg, Germany 
Olympus Ck30 microscope Olympus, Tokyo, Japan 
Pipettes (5ml, 10ml, 25ml) Greiner Bio, Frickenhausen, Germany 
Pipette tips (10µl, 100µl, 1000µl) Sarstedt, Numbrecht, Germany 
PowerPac HC, Tank Blotting System Bio-Rad, Hercules, CA, USA 
PVDF (0.2µm, 0.45µm) membrane Amersham Bioscience, Freiburg, Germany 
SpectraFluor Plus™ Tecan, Männedorf, Switzerland 
Tecan Sunrise Tecan, Männedorf, Switzerland 
Transwell Permeable Supports 8 μm 
pore polycarbonate inserts 
Corning Incorporated, New York, NY, USA 
Vi-Cell™ XR Beckman Coulter, Krefeld, Germany 
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xCELLigence system Roche Diagnostics, Mannheim, Germany 
 
2.1.7 Software 
Software Supplier 
FlowJo 7.6.5 Tree Star, Ashland, OR, USA 
GraphPad Prism 7 GraphPad Software, San Diego, CA, USA 
ImageJ NIH, Bethesda, MD, USA 
Image Lab 5.2 Bio-Rad, Hercules, CA, USA 
Leica LAS X Leica, Wetzlar, Germany 
Microsoft Office 2010 Microsoft, Redmont, WA, USA 
RTCA software 2.0 ACEA Biosciences, San Diego, CA, USA 
Wave 2.3.0 Agilent Technologies, Santa Clara, CA, USA 
 
2.2 Cell Culture 
For the cultivation of CCRF-CEM cells and BxPC3 cells RPMI 1640 supplemented with 
10% fetal calf serum (FCS) and a combination of 100 U/ml penicillin and 100µg/ml 
streptomycin (P/S) was used, while all Jurkat cell lines were cultivated in the same 
medium with additional 1mM pyruvate. HL-60 cells were maintained in IMDM medium 
supplemented with 20% FCS and P/S. Panc 03.27 and Panc 10.05 cells were cultivated in 
RPMI 1640 supplemented with 15% FCS and 10 Units/ ml human recombinant insulin and 
P/S. HeLa and T24 cells were maintained in DMEM supplemented with 10% FCS and 
P/S. All cells were cultured at 37°C with 5% CO₂ at constant humidity in an incubator. 
2.2.1 Passaging 
Suspension cells lines were maintained at a cell density between 0.1-1.0 x 10⁶ cells/ml 
and typically passaged three times per week. Adherent cells were cultured as monolayer 
in 75cm² culture flasks until they reached 80-90% confluence. For detachment of cells, 
they were washed twice with pre-warmed PBS and subsequently incubated with trypsin/ 
EDTA (Table 6) for 2-3 min at 37°C. The enzymatic reaction was stopped by adding 
complete growth medium. The cell density was determined using the ViCell XR cell 
viability analyzer prior to seeding in multiwell-plates or dishes for further experiments or 
culture flaks for further cultivation. 
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 Table 7 Solutions and reagents for cell culture 
 
 
2.2.2 Freezing and thawing of cells 
For freezing, the cell density was adjusted to 2 x 10⁶ cells/ ml in growth medium 
supplemented with 20% FCS, Pen/ Strep and 10% DMSO. Aliquots of 1.5 ml in cryo vials 
were prepared and immediately frozen at -20°C for 1-2 hours, transferred to -80°C 
overnight and finally stored in liquid nitrogen. For recultivation, cells were thawed in a 
water bath at 37°C, transferred into a tube containing 20 ml of growth medium and 
centrifuged. The supernatant was discarded and cells were resuspended in 5ml of fresh 
growth medium and seeded into a 25 cm² flask for further expansion.  
2.2.3 Stimulation with compounds 
Adherent cell lines were seeded the day before treatment to ensure complete attachment. 
Suspension cells were treated after 4h incubation. DMSO stock solutions of test 
compounds were thawed and pre-diluted in complete growth medium. DMSO 
concentration did not exceed 0.1% (v/v) in all experiments. 
2.2.4 Transfection with siRNA 
For gene silencing, cells were transfected according to the DharmaFECT™ Transfection 
Reagents- siRNA transfection protocol. Cells were seeded in antibiotic free medium at a 
density of 0.15 x 10⁶ cells / ml the day before transfection. For one 6-well, 10µl siRNA 
(c=5µM] was diluted in 190µl serum-free medium and 4µl DharmaFECT I reagent was 
diluted in 196µl serum-free medium and incubated for 5 min at RT. The content of the two 
tubes was gently mixed by carefully pipetting up and down, incubated for 20 min at RT 
and subsequently transferred to the culture plate. 
2.3 Proliferation assay 
2.3.1 Crystal violet assay 
To determine the proliferative capacity of adherent cells, respective cell types were 
seeded into 96-well plates (2500 cells/ well) and treated with the indicated test 
compounds on the subsequent day for 72h. Afterwards the media was discarded, cells 
were washed with PBS and then stained and fixed with crystal violet solution (Table 8) for 
PBS (pH 7.4)  
NaCl 132.2mM 
Na₂HPO₄ 10.4mM 
KH₂PO₄ 3.2mM 
H₂O  
Trypsin/EDTA  
Trypsin 0.05% /w/v) 
Na₂EDTA 0.02% (w/v) 
PBS  
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10 min. Stained cells were washed with distilled water and dried, before crystal violet was 
re-dissolved in sodium citrate solution for 10 min. Absorbance was measured at 540 nm 
using the Tecan Sunrise microplate reader. As a reference for the cell number at day 0, 
three wells were seeded on a separate plate and crystal violet staining was performed at 
the time point of treatment (day 0 Ctrl.). Day 0 Ctrl value was subtracted from the 
measured values and proliferation [%] was determined relative to DMSO control. 
Table 8 Solutions for crystal violet assay 
Crystal violet solution  
Crystal violet 0.5% (w/ v) 
Methanol 20% (v/ v) 
H₂O  
 
2.3.2 Cell titer blue (CTB) assay 
To analyze the proliferation rate of suspension cells, respective cell lines were seeded at 
a density of 5000 cells/ well in a 96-well plate. Subsequently, cells were stimulated with 
the indicated test compounds for 72h. Next, cell titer blue (CTB) reagent was added to 
each well (volume ratio 2:5) and incubated for 4h at 37°C. Viable cells are able to reduce 
the dye resazurin into the highly fluorescent resofurin, which fluorescence was recorded at 
595 nm using the Tecan SpectraFluor Plus microplate reader. As a reference for the cell 
number at day 0, three wells were seeded on a separate plate and CTB was added at the 
time point of stimulation (day 0 Ctrl.). The day 0 Ctrl. value was subtracted from the 
measured values and viable cells [%] were determined relative to DMSO control. 
2.3.3 xCELLigence proliferation assay 
For real-time monitoring of proliferation, adherent cells were seeded at a density of 5000 
cells/ well in equilibrated E‐plates 16 an allowed to adhere for 24h. Next, cells were 
challenged with cytotoxic agents as indicated and their response was continuously 
monitored for the subsequent 72h at 37°C using the RTCA xCELLigence device. Through 
impedance measurement, the xCELLigence system evaluates the cell index, a 
dimensionless parameter that is proportional to the cell number. The cell index was 
normalized at the time-point of treatment and The RTCA software was used for further 
data analysis. 
Sodium citrate solution  
Sodium citrate 0.1 M 
Ethanol 50% (v/ v) 
H₂O  
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2.4 Migration and invasion assays 
2.4.1 Transwell migration assay 
Migration of cells was evaluated by using the Boyden chamber technique, where cells are 
placed inside a transwell and allowed to migrate through restricted pores towards a 
chemoattractant. In detail, T24 cells were detached and counted and 7 x 10⁴ cells in 100µl 
medium without FCS were stimulated with the test compound and seeded into the top of a 
Boyden chamber insert with 8µm pore size. The lower compartment was filled with 
medium containing 10% FCS, which served as chemoattractant. T24 cells were allowed to 
migrate through the pores for 16h. Subsequently, migrated cells were fixed and stained 
with crystal violet solution as described in 2.3.1 and cells that remained in the upper 
compartment were carefully removed with a q-tip. Cells that reached the bottom of the 
insert were imaged using an Axiovert 25 microscope and an EOS 450C camera. For each 
condition 4 images were taken and cells were counted using ImageJ software. Number of 
migrated cells was normalized towards DMSO control. 
2.4.2 xCELLigence migration assay 
For real time monitoring of cell migration, a CIM plate 16 was assembled and equilibrated 
according to manufacturer’s protocol. Normal growth medium containing 10% FCS was 
added to the lower chambers of the plate and served as a chemoattractant. Cells were 
detached, counted and the cell number was adjusted to 40.000 cells/ 100µl medium 
without FCS per well. Subsequently, cells were transferred into the upper chamber of the 
plate and allowed to settle onto the bottom for 30 min at RT. Afterwards, the CIM plate 
was placed into the xCELLigence instrument and migration was recorded at 37°C for at 
least 16h. By impedance measurement, the xCELLigence device evaluates the cell index, 
a dimensionless parameter that is proportional to the number of migrated cells. Further 
data evaluation was performed with the RTCA xCELLigence software. 
2.4.3 Three-dimensional spheroid invasion assay 
To evaluate the ability of tumour cells to invade surrounding tissues, a spheroid-based 
invasion assay as described by Vinci et al. was performed (57). T24 cells were detached 
and counted before dilution of the cell suspension for obtaining a concentration of 1 x 10⁴ 
cells/ ml. Next, the cell suspension was dispensed into an ultra-low attachment (ULA) 96- 
well round bottom plate (200µl/ well). Spheroids were allowed to grow for 72h at 37°C. 
Subsequently the ULA 96-well plate was placed on ice and 100µl growth medium was 
removed from each well. Matrigel™, thawed on ice and mixed with 2x the final 
concentration of test substance or vehicle, was added to each well (100µl/ well). After 
centrifugation (300xg, 4°C, 3 min) to ensure that spheroids are centrally located in each 
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well, the Matrigel™ was allowed to polymerize at 37°C for 1h. Afterwards 100µl/ well 
complete growth medium was added containing the test substance or vehicle. Spheroid 
invasion was monitored after 24, 48 and 72h with a Leica DMi1 microscope and spheroid 
size was calculated with ImageJ. 
2.5 Flow cytometry 
2.5.1 Apoptosis and cell cycle analysis 
Apoptosis rate was determined by propidium iodide (PI) staining and flow cytometry as 
described by Nicoletti et al. (58, 59) Cells were seeded into 24-well plates at a density of 
100.000 cells/ well and treated with test compounds as indicated the day after seeding for 
24 or 48h. Subsequently, cells were detached (if applicable), washed with ice cold PBS 
and permeabilized and stained by adding fluorochrome solution (Table 9). After 30 min 
incubation at 4°C in the dark, cells were analysed by flow cytometry on a BD FACSCanto 
II. Per sample 10.000 events were recorded at Ex488 nm/ Em585 nm. The fluorescence 
intensity indicates the DNA content. In apoptotic cells, DNA is fragmented, which leads to 
a relatively low fluorescence (subG1 population). Cell cycle analysis and apoptotic cells 
were determined with FlowJo software. 
 
Table 9 Fluorochrome solution 
Fluorochrome solution  
Propidium iodide 50µg/ ml 
Sodium citrate 0.1% (w/ v) 
Triton X-100 0.1% (v/ v) 
PBS  
 
2.5.2 Apoptosis of PDX cells and PBMCs 
PDX cells and PBMCs were stimulated with test compounds for 24h and subsequently 
transferred to FACS tubes, washed with PBS and resuspended in 250µl PBS. Next, cells 
were analyzed on a FACSCanto II and the percentage of viable and apoptotic cells was 
determined by forward/ side scatter (FSC/ SSC) gating as described previously (56). In 
Figure 6, FSC/ SSC dot plots of DMSO control versus Vioprolide A (VioA) treated ALL-
707 PDX cells are exemplarily shown. Specific apoptosis rate was calculated according to 
the following formula: 
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Fig.6 Gating of viable and apoptotic cells in PDX samples. Representative FSC-SSC dot plots 
of PDX cells treated with VioA versus DMSO control are shown.  
2.5.3 Mitochondrial membrane potential 
JC-1 staining was used to determine the mitochondrial membrane potential (Δᴪm). 
Tetraethylbenzimidazolylcarbocyanine iodide (JC-1) is a cationic dye that accumulates in 
mitochondria. When mitochondrial membrane potential is high, JC-1 aggregates in 
mitochondria, yielding a red to orange coloured fluorescence. Upon loss of mitochondrial 
membrane potential, the dye predominantly exists as a monomer in the cytosol emitting 
green fluorescence. In detail, treated cells were detached (if applicable) and transferred 
into FACS tubes. Subsequently cells were stained with 1µg/ ml JC-1 dye and incubated at 
37°C for 30 min, washed with PBS and resuspended in PBS. In parallel, compensation 
samples were prepared using the BD CompBeads Anti-mouse Ig, κ particles set and 
Alexa Fluor and PE-conjugated antibodies. Prior to analysis of JC-1 stained cells, 
compensation of spectral overlap was performed at the FACSCanto II. Relative amount of 
populations exposing red or green fluorescence was determined with FlowJo software. 
Alexa 488 was plotted against PE fluorescence. 
2.5.4 Mitochondrial mass  
Mitochondrial mass was determined by MitoTracker Green FM staining and flow 
cytometry. Cells were seeded into 24 well plates at a density of 100.000 cells/ well and 
treated with test compounds as indicated the day after seeding. Afterwards cells were 
detached (if applicable), washed with ice cold PBS and permeabilized and stained by 
adding 400nM MitoTracker Green FM. After 30 min incubation at 37°C, cells were 
centrifuged and resuspended in PBS before analysis by flow cytometry on a BD 
FACSCanto II. Per sample 10.000 events were recorded at Ex 488 nm/ Em 516 nm. 
Median of intensity was determined with FlowJo software and mitochondrial mass was 
calculated relative to DMSO control. 
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2.6 Western blot analysis 
2.6.1 Cell lysis 
Cellular protein levels were analysed by Western Blot. For lysis of adherent cell types, 
medium was removed and cells were washed with ice cold PBS before adding lysis buffer 
(Table 10) and freezing at -80°C overnight. Subsequently, cells were scraped off with a 
cell scraper and transferred into Eppendorf tubes before centrifugation (14.000 rpm, 10 
min, and 4°C) in order to remove debris. Suspension cells were centrifuged, washed with 
ice cold PBS and resuspended in lysis buffer before freezing at -80°C overnight and 
centrifugation (14.000 rpm, 10 min, 4°C). After the centrifugation step, the whole cell 
lysate was stored at -20°C, if not immediately processed further.  
Table 10 Buffers for cell lysis 
Lysis buffer stock  
EDTA 2mM 
NaCl 137mM 
Glycerol 10% (v/ v) 
Na₄P₂O₇ x 10 H₂O 2mM 
Tris- Base 20mM 
Triton-X 100 1% (v/ v) 
C₃H₇Na₂O₆P x 5 H₂O 20mM 
NaF 10mM 
H₂O  
 
2.6.2 Protein quantification and sample preparation 
To ensure equal protein loading, protein concentration was determined by Bradford assay. 
In detail, 5µl of whole cell lysate was diluted in water 1:5 (v/ v) and 10µl of the prepared 
dilution was transferred to a 96-well plate in triplicates. In parallel, bovine serum albumin 
(BSA) standards (0-500µg/ ml) were transferred to the 96-well plate. Bradford reagent, 
diluted 1:5 (v/ v) in water was added to the samples (190µl/ well) and incubated for 5 min 
at RT. Bradford assay is addition of coomassie brilliant blue G-250 to protein solution. The 
coomassie blue dye associates with basic and aromatic amino acids, thereby causing a 
shift in absorbance during protein determination. The resulting absorbance was measured 
at a Tecan Sunrise microplate reader and protein concentrations of the samples were 
calculated by linear regression. Subsequently 5x SDS sample buffer (Table 11) was 
added to the samples and protein concentration was adjusted by adding 1x SDS sample 
Lysis buffer final composition  
lysis buffer stock 920µl 
Na₃VO₄ 100mM 20µl 
PMSF 50mM 20µl 
Complete® 25x 40µl 
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buffer. Afterwards the samples were heated at 95°C for 5 min and stored at -20°C before 
gel electrophoresis. 
Table 11 Sample buffers for Western Blot  
5x SDS sample buffer  
Tris-HCl (pH 6.8) 3.125M 
Glycerol 50% (v/ v) 
SDS 5% (w/ v) 
DTT 2% (w/ v) 
Pyronin Y 0.025% (w/ v) 
H₂O  
 
2.6.3 SDS PAGE and tankblotting 
For separation of proteins, discontinuous SDS- polyacrylamide gel electrophoresis (SDS 
PAGE) was performed. Equal amounts of protein samples were loaded on polyacrylamide 
(PAA) gels consisting of a separation and a stacking gel. The PAA concentration used 
was typically 12%, but was adjusted depending on the molecular weight of the analysed 
proteins. The Mini Protean 3 system chamber from Bio-Rad was filled with electrophoresis 
buffer (Epho buffer) and gels were loaded with samples. Electrophoresis was performed at 
a current of 100 V for 21 min and at 200 V for 45 min for protein stacking and separation, 
respectively. To determine the molecular weight of the proteins detected, a pre-stained 
protein ladder PageRuler™ or PageRuler Plus™ was subjected to gel electrophoresis in 
parallel. 
  
1x SDS sample buffer  
5x SDS sample buffer 20% (v/ v) 
H₂O  
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Table 12 Buffers and gel mixtures for gel electrophoresis 
 
 
 
 
 
 
Epho buffer  
Tris 4.9mM 
Glycine 38mM 
SDS 0.1% (w/ v) 
H₂O  
 
Prior to tank blotting, protein load was determined by stainfree detection of 
trichloroethanol (TCE) supplemented gels using the ChemiDoc Touch Imaging System. 
Subsequently, proteins were transferred onto a PVDF membrane by tank blotting. PVDF 
membranes were activated in methanol for 1 min before a blotting sandwich (fiber pad- 
blotting paper – separation gel – PVDF membrane – blotting paper – fiber pad) was 
prepared and put into the Mini Trans-Blot® system that was subsequently filled with 1x 
tank buffer (Table 13). The proteins were transferred at 4°C utilizing a constant current of 
100V for 90 min.  
 
 Table 13 Buffers for tank blotting 
5x tank buffer  
Tris base 240 mM 
Glycine 195 mM 
H₂O  
 
Stacking Gel  
Rotiphorese Gel 30 17% (v/ v) 
Tris-HCl (pH 6.8) 125 mM 
SDS 0.1% (w/ v) 
TEMED 0.2% (v/ v) 
APS 0.1% (w/ v) 
H₂O  
Separation Gel 12%  
Rotiphorese Gel 30 40% (v/ v) 
Tris-HCl (pH 8.8) 375 mM 
SDS 0.1% (w/ v) 
TEMED 0.1% (v/ v) 
APS 0.05% (w/ v) 
TCE 0.5% (w/ v) 
H₂O  
1x tank buffer  
5x tank buffer 20% (v/ v) 
Methanol 20% (v/ v) 
H₂O  
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2.6.4 Protein detection 
Membranes were blocked with a 5% (w/ v) solution of milk powder in TBS-T buffer for 2h 
at RT to avoid unspecific binding of primary antibodies. Subsequently, membranes were 
incubated with primary antibody solution at 4°C under gentle agitation overnight. Primary 
antibodies were usually diluted 1:000 (v/ v) in 1% (w/ v) milk powder solution in TBS-T. On 
the next day, membranes were washed three times with TBS-T and incubated with an 
appropriate HRP-linked secondary antibody for 2h at RT. After additional three washing 
steps with TBS-T, enhanced chemiluminescence (ECL) imaging was used to detect 
antibody signals on membranes. In detail, proteins were detected by HRP-linked oxidation 
of luminol and chemiluminescence detection by incubating membranes for 1 min in ECL 
solution and developing membranes directly on the ChemiDoc Touch imaging system 
from Bio-Rad. Further data evaluation was performed with Image Lab software. 
2.7 Co- immunoprecipitation 
2.7.1 MS based co-immunoprecipitation 
VioA target interactome analysis was performed by Volker Kirsch in the laboratory of Prof. 
Dr. Stephan Sieber (TU Munich, Germany) using MS-based co-immunoprecipitation of the 
target protein NOP14. 
For MS-based co-Immunoprecipitation experiments 4x106 cells were plated out on 6 cm 
dishes (Sarstedt) in 8 mL media supplemented with VioA (10 nM, 10 µM stock solution in 
DMSO, 0.1% final concentration of DMSO) or DMSO respectively. After incubation (37°C, 
5% CO2, 24 h) 37°C, 5% CO2, cells were counted and readjusted to a number of 4x10
6 
cells per dish. Cells were subsequently, pelleted (800 x g, 6 min, RT), supernatant 
discarded, and cells washed in PBS twice. For in situ cellular cross-linking cells were 
resuspended in PBS and supplemented with 2mM DSSO crosslinker. After incubation 
(37°C, 5% CO2, 1 h) cells were pelleted (600 g, 5 min, 4°C), supernatant discarded, and 
remaining DSSO crosslinker quenched by resuspending cells in cold tris buffer (1 mL, 
50 mM Tris-HCl, pH = 8.0). Cells were pelleted (600 g, 5 min, 4°C), resuspended in cold 
PBS, pelleted and supernatant discarded. For cell lysis, cells were taken up in IP lysis 
buffer (500 µL, 50 mM Tris-HCl, 150 mM NaCl, 1 mM MgCl2, 5% (v/v) glycerol, 1% (v/v) 
NP-40, pH = 7.4) and incubated for 30 min on ice. Cell lysate was cleared from debris 
(21,000 g, 20 min, 4°C), protein concentrations determined using Bradford assay and 
samples normalized to a total protein amount of 500 µg per sample (protein concentration 
1 µg/ µL). 30 µL Protein A/G Agarose beads were equilibrated with cold IP wash buffer 
(1 mL, 50 mM Tris-HCl, pH = 7.4, 150 mM NaCl, 1 mM MgCl2, 5% (v/v) glycerol, 0.05% 
NP-40), centrifuged (1,000 g, 1 min, 4°C), supernatant discarded and 500 µL of sample 
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added directly to the beads. Additionally, 10 µl of NOP14 antibody (Cat. No. HPA039596, 
Sigma Aldrich) was added. For determination of unspecific background binding to the 
beads and antibody constant regions, 0.4 µl isotype control rabbit mAb IgG (Cat. No. 
2729, Cell Signaling) was added to control samples, and all samples incubated at 4°C 
under constant rotation overnight. Subsequently, samples were centrifuged (1,000 g, 
1 min, 4°C) and supernatant discarded. For removal of unspecific bound proteins, pelleted 
beads were resuspended in IP wash buffer, centrifuged (500 g, 30 sec, 4°C), and 
supernatant discarded. The procedure was carried out twice, and twice again with IP 
basic buffer (50 mM Tris-HCl, pH = 7.4, 150 mM NaCl, 5% (v/v) glycerol) for detergent 
removal. Samples were reduced and digested by the addition of IP elution buffer I (25 µL, 
50 mM Tris-HCl, pH = 8.0; 5 ng/µL Trypsin (500 ng/µL stock solution, sequencing grade, 
modified, Promega), 2 M Urea, 1 mM DTT (500 mM stock solution in H2O). Samples were 
incubated (30 min, 600 rpm, rt) prior to addition of IP elution buffer II (100 µL; 50 mM Tris-
HCl; pH = 8.0; 2 M Urea; 5 mM IAA (500 mM stock solution in H2O), followed by 
incubation at 37°C and 600 rpm overnight. Tryptic digest was stopped by the addition of 
FA (1% final concentration). Samples were desalted using C18-stage tips (double layer; 
Empore disk-C18; 47 mm; Agilent Technologies) using the following procedure: 
Equilibration with MeOH (70 µL), followed by washing with 0.5% FA (3x 70 µL), sample 
load and a washing step (3x 70 µL, 0.5% FA). Finally, peptides were eluted with elution 
buffer (3x 30 µL; 80% MeCN, 0.5% FA). Samples were dried using a centrifugal vacuum 
concentrator (Eppendorf). Prior to LC-MS/MS analysis dried peptide samples were 
reconstituted in 1% FA in ddH2O (26 µL), sonicated for 10 min and filtered using 0.22 µm 
Ultrafree-MC® centrifugal filters (Merck, UFC30GVNB), pre-equilibrated with 300 µL 1% 
FA in ddH2O and transferred into LC-MS vials. The experiment was carried out in 
quadruplicates. 
2.7.2 Western blot based co-immunoprecipitation 
For investigation of protein- protein interactions co-immunoprecipitation (co-IP) 
experiments were performed. Jurkat cells were seeded at a density of 1 x 10⁵ cells/ ml 
and treated as indicated. Subsequently, cells were pelleted, washed with ice-cold PBS 
and cell lysis was performed by incubating cells with Triton-X 100 lysis buffer (Table 14) 
for 30 min on ice. After removal of cell debris by centrifugation (10.000 rpm, 10 min., 4°C) 
protein concentration was determined by Bradford assay as described in 2.6.2. Next 
500µg protein per sample was adjusted to 500µl final volume with Triton-X 100 lysis buffer 
and mixed with 10µl NOP14 antibody (Cat. No. HPA039596, Sigma Aldrich) and 50µl 
µMACS Protein G magnetic beads and was incubated under gentle agitation at 4°C for 
4h. In parallel 500µg protein, mixed with 5µl normal rabbit IgG1 control antibody (Cat. No. 
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2729, Cell Signaling) and 50µl magnetic beads was prepared as negative control. For co-
IP the magnetic labelled NOP14 and its interacting proteins were retained on Miltenyi 
µColumns. In detail, µColumns were placed into the µMACS separator magnetic field and 
equilibrated with Triton-X 100 buffer before loading with the samples. After four washing 
steps with Triton-X 100 buffer the columns were finally rinsed with low salt wash buffer 
(Table 14). Proteins were eluted with 1x SDS sample buffer pre-heated to 95°C and 
subjected to Western Blot as described in 2.6.3 and 2.6.4.  
Table 14 Buffers for Co-IP 
Triton-X 100 buffer (pH 8.0)  
NaCl 150mM 
Tris HCl 50mM 
Triton-X 100 1% (v/ v) 
Complete 25x 4% (v/ v) 
H₂O  
 
 
 
2.8 Confocal microscopy 
2.8.1 Immunostaining 
For immunostaining cells were seeded in ibidiTreat 8- well slides and allowed to adhere 
overnight. Cells were stimulated and subsequently washed with PBS and fixed with 4% 
paraformaldehyde (PFA) in PBS for 10 min. After permeabilization with 0.1% Triton X-100 
in PBS at RT for 15 min, cells were washed with PBS and incubated with 1% BSA in PBS 
for 2h under gentle agitation. Subsequently, primary antibody, diluted 1:400 (v/ v) in 1% 
BSA in PBS was added and cells were incubated overnight at 4°C. On the next day, cells 
were washed three times with PBS+ 0.2% TX-100 and the appropriate Alexa 488 or Alexa 
647 secondary antibody; diluted 1:500 in PBS was added for 2h at RT in the dark. For 
nuclei staining, Hoechst 33342 was added (final c= 5µg/ ml) for 30 min and cells were 
finally washed three times for 10min with PBS. One drop of FluorSave reagent mounting 
medium was added to each well before sealing with a cover slip. After 30 min incubation 
at RT, Confocal microscopy was performed on a Leica SP8 LSM system and images were 
analyzed with Leica LAS X or ImageJ software. 
Low salt wash buffer (pH 7.5)  
Tris HCl 20mM 
H₂O  
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2.8.2 Nuclear run on assay 
Cells were seeded as described in 2.8.1 and treated with the indicated substances and 
5mM 5-Fluorouracil (5-FU) was added for the last 60 min. Fixation and permeabilization 
was performed as described in 2.8.1. Subsequently cells were stained with anti-BrdU 
antibody as primary antibody and Alexa Fluor 488 as secondary antibody. Percentages of 
positive cells were calculated. Treatment with actinomycin D (7.5g/ml) served as positive 
control for transcriptional inhibition. 
2.8.3 Live cell imaging 
For imaging of mitochondrial dynamics in living cells a stage top cell chamber was 
installed on a Leica SP8 microscope to maintain the required culturing conditions (37°C, 
5% CO2, 95% humidity). Cells were seeded into an ibidiTreat 8- well slide and allowed to 
adhere overnight before treatment with the test compound and staining with 400nM 
MitoTracker Green FM in normal growth medium for 30 min. After incubation, cells were 
immediately imaged live. 
2.9 Transmission electron microscopy  
For Transmission electron microscopy (TEM) cells were detached, counted and washed 
with PBS before 4 x 10⁵ cells per sample were transferred to a BEEM® capsule. Cells 
were pelleted, and supernatant was removed before 600µl 2.5% glutaraldehyde was 
added to the sample. Embedding and further preparation of the samples was performed 
by Carola Eberhagen and electron microscopy was performed by Dr. Sabine Schmitt in 
the laboratory of Prof. Dr. Hans Zischka (Institute of Molecular Toxicology and 
Pharmacology, Helmholtz Centre, Munich). 
2.10 Seahorse mito stress test 
HeLa cells were seeded into an XFe 96 microplate at a density of 1.2 x 10⁴ cells/ 80µl 
growth medium/ well and were allowed to adhere for 24h. Subsequently cells were 
stimulated with test compounds as indicated for 24h. The Seahorse Mito Stress Test was 
performed by using the provided kit and the Seahorse XFe96 Analyzer according to 
manufacturer’s protocol. An overview of the injected substances and the analyzed 
parameters is given in Figure 7. The measured oxygen consumption rate (OCR) results 
were normalized to the cell number, determined by CyQuant® GR dye DNA content 
measurement. Further data analysis was performed with the Wave 2.3.0 software and the 
Seahorse XF Mito Stress Test Report Generator, both provided by the manufacturer. 
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Fig. 7 Agilent Seahorse Mito Stress Test prolife. Sequential addition of different inhibitors and 
measured parameters are shown. 
 
2.11 Thermal proteome profiling   
VioA target identification was performed by Volker Kirsch in the laboratory of Prof. Dr. 
Stephan Sieber (TU Munich, Germany) using thermal proteome profiling (TPP). 
In situ thermal proteome profiling experiments were carried out as reported (60) previously 
with minor modifications. 6x107 Jurkat cells were washed with PBS, resuspended in 
medium w/o FCS and supplemented with VioA (1µM) or DMSO respectively and 
transferred into T75-flasks. After incubation (37°C, 5% CO2, 1 h) cells were pelleted 
(800 g, 6 min, rt), supernatant discarded, cells resuspended in PBS and centrifuged again. 
Cell pellets were resuspended in PBS and cell suspension distributed into 0.2-mL PCR 
tubes (Kisker Biotech, 6x106 Mio cells per tube) and kept at room temperature prior to heat 
treatment. VioA and DMSO treated samples were heated in parallel for 3 min. to the 
respective temperature (37°C, 41.2°C, 44°C, 48°C, 53.1°C, 56.3°C, 59.3°C, 62.5°C and 
67.1°C) in a PCR cycler (Techne), incubated for 3 min. at room temperature, and 
subsequently snap-frozen in liquid nitrogen and stored at -80°C. Cell lysis was 
accomplished using four freeze-thaw cycles (incubation for 30 seconds at 25°C, followed 
by snap-freezing in liquid nitrogen). Subsequently, 50µl PBS was added and the samples 
subjected to ultracentrifugation (100,000 g, 20 min, and 4°C). 100 µL of the resulting 
supernatant was transferred into new 1.5 mL tubes. For protein amount normalization, 
protein concentration of the two lowest temperature point samples (37°C and 41°C) were 
determined with a sample aliquot (10 µL) using Bradford assay. Proteins were precipitated 
by adding acetone (400 µL) and incubated overnight (-20°C). Next, precipitated proteins 
were pelleted (21,000 g, 20 min., 4°C), supernatant discarded and protein pellet 
resuspended by sonication (10% intensity, 10 sec, Sonopuls HD 2070 ultrasonic rod, 
BANDELIN electronic GmbH & Co. KG) in pre-chilled methanol (500 µL). Protein pellet 
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washing step was carried out twice. Subsequently, proteins were resuspended in X-buffer 
(300 µL, 7 M urea, 2 M thiourea in 20 mM Hepes buffer pH 7.5) by sonication (procedure 
as described above). Proteins were reduced with DTT (1 mM, 1 M stock in ddH20) and 
incubated under gentle mixing (25°C, 45 min, 450 rpm). Alkylation of proteins was 
achieved by the addition of iodoacetamide (5.5 mM, 550 mM stock in ddH20) and 
incubated under gentle mixing (25°C, 30 min, 450 rpm). Alkylation reaction was stopped 
by the addition of DTT (4 mM, 1 M stock in ddH20) and incubated under gentle mixing 
(25°C, 30 min, 450 rpm). Proteins were predigested with LysC (3.33 µg/mL, 0.5 mg/mL 
stock in ddH20; Wacko) under gentle mixing (25°C, 2 h, 450 rpm). TEAB buffer (900 µL, 
50mM) was added, and samples further digested with trypsin (4 µL, 0.5 mg/mL stock, 
sequencing grade, modified; Promega) overnight under mixing (37°C, 800 rpm). Digest 
was stopped the following day by the addition of formic acid (0.1% final concentration; 
Sigma-Aldrich) and peptides desalted using Sep-Pak C18 1 cc Vac cartridges (Waters) 
and the following procedure: Resin was washed with MeCN (1 mL) and elution buffer 
(80% MeCN, 0.5% FA) prior to equilibration with 0.1% TFA (3 mL). Peptide solutions were 
loaded to the cartridges and bound peptides washed with 0.1% TFA (3 mL) and 0.5% FA 
(0.5 mL) and finally eluted with elution buffer (0.75 mL). Peptides were dried using a 
centrifugal vacuum concentrator (Eppendorf) and stored at -80°C. Peptides were 
reconstituted in elution buffer and a volume of each sample corresponding to 25 µg 
protein in the two lowest temperature points transferred into new 1.5 mL LoBind tubes. 
Samples were dried and taken up in TMT buffer 1 (10 µL, 10% MeCN 90% 200 mM TEAB 
buffer) and incubated under gentle mixing (25°C, 15 min, 400 rpm). Additional TMT buffer 
1 (25 µL) was added to each sample. TMT labels were allowed to gain room temperature 
and taken up in MeCN (41 µL). 10 µL of each label solution was added to a sample 
according to applied temperature point (see Table S6) and incubated under gentle mixing 
(25°C, 1 h, 400 rpm). Reaction was stopped by the addition of 5% (v/v) hydroxylamine 
solution (5 µL, Sigma Aldrich) and incubated under gentle mixing (25°C, 15 min, 400 rpm). 
Labeled peptides were combined into a single sample per experiment, TMT solution 2 
(100 µL, 60% (v/v) 200 mM TEAB buffer 40% (v/v) MeCN) added and samples dried using 
a centrifugal vacuum concentrator. Dried labeled peptides were reconstituted in 0.5% 
formic acid (200 µL) and desalted using C18 StageTips (eight layers; Empore disk-C18; 
47 mm; Agilent Technologies) and the following procedure: layers were washed with 
MeOH (90 µL), elution buffer (200 µL) and 0.5% FA (600 µL). Samples were loaded on 
stage tips (500g, 2 min) and bound peptides washed with 0.5% formic acid (600 µL) and 
eluted with elution buffer (300 µL). Eluted peptides were dried in a centrifugal vacuum 
concentrator. For HILIC fractionation, samples were reconstituted in HILIC buffer A 
(110 µL, 95% MeCN 5% H2O and 0.1% TFA), sonicated, vortexed and centrifuged 
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(21,000 x g, 10 min, 4°C). Peptide fractionation was carried out using an UltiMate 3000 
HPLC system (Dionex) equipped with an YMC-Pack PVA-Sil column (5 µm, 
150 x 2.1 mm, 120 Å, YMC Europe GmbH). Gradient elution was carried out with 95% 
MeCN 5% H2O and 0.1% TFA (A) and 95% H2O 5% MeCN and 0.1% TFA (B). 100 µL 
sample were injected and separated using a 62.5 min gradient (7.5 min 0% B, 50 min to 
30% B, 3.5 min to 50% B and 2.5 min to 100% B) at a flow rate of 0.2 mL/min, followed by 
a washing and column re-equilibration step (12.5 min 100% B, 0.5 min to 0% B and 
22.5 min 0% B). During separation, an on-line UV detector set at 215 nm was utilized to 
monitor peptide mixture elution. Fractions were collected into a 96-well plate (Eppendorf) 
and resulting fractions were pooled into 10 greater fractions. Fractions were dried in a 
centrifugal vacuum concentrator and fractions 2-9 subjected to LC-MS/MS analysis. Prior 
to LC-MS/MS analysis dried peptide samples were reconstituted in 1% FA in ddH2O 
(10 µL), sonicated for 10 min and filtered using 0.22 µm Ultrafree-MC® centrifugal filters 
(Merck, UFC30GVNB), preequilibrated with 300 µL 1% FA in ddH2O and transferred into 
LC-MS vials. The experiment was carried out in duplicates. 
 
2.12 Data collection and statistical analysis 
All experiments were performed at least three times (biological replicates) in technical 
triplicates unless indicated otherwise. Statistical analysis, as well as calculation of IC₅₀ 
and EC₅₀ values was conducted with GraphPad Prism software. Bar graphs are shown as 
mean ± SEM. A two-tailed unpaired Student’s t-test or one-way ANOVA, Dunnett’s test 
was performed (* P<0.033, ** P<0.002, *** P<0.001, **** P<0.0001). For western blot and 
confocal microscopy experiments, representative images of at least three biological 
replicates are shown. For xCELLigence and Seahorse experiments, representative curves 
of three independent data sets are depicted. 
  
3. Results Part I - Vioprolide A 
41 
 
3. Results Part I - Vioprolide A 
3.1 Functional characterization  
3.1.1 Vioprolides inhibit cancer cell proliferation 
In 1996, the isolation of Vioprolides A-D and their potent antifungal and anticancer 
activities were reported by Schummer et al. (16). However, no further investigations 
concerning their antitumor activity have been described up to date. Furthermore, the initial 
publication indicated a diverse specificity of the family members towards fungi, yeast and 
mammalian cells (16). Hence, in order to select the most potent growth inhibitory 
compound in human cancer cells for subsequent mode of action analyses, this study 
initiated with a comparative analysis of Vioprolide A, B, C and D (VioA-D), performed in 
the human acute lymphoblastic leukemia (ALL) cell line Jurkat. Of note, VioA exhibited the 
highest antiproliferative activity with a half maximal inhibitory concentration (IC50) of 
4.4nM, determined by cell titer blue assay after 72h (Figure 8B). In line with previous data 
(16), the Vioprolide derivatives showed significant differences in bioactivity, demonstrating 
that the structural composition of their N-heterocycles (Figure 8A) is crucial for their 
potency. 
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Fig. 8 Dose-dependent inhibition of leukemic cell proliferation by Vioprolide derivatives. 
(A) Chemical structures of Vioprolide A, B, C and D. (B) Dose response curves and corresponding 
IC50 values of Jurkat cells incubated with Vioprolide A, B, C and D determined by cell titer blue 
assay after 72h. Data points always represent the mean ± SEM of three independent experiments 
performed in triplicates. 
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Subsequently, VioA was tested against a panel of cancer cell lines, including leukemia cell 
lines (CEM, Jurkat, HL-60) and solid cancer cell lines (T24, HeLa). Thereby, VioA 
displayed low nanomolar IC₅₀ values in all tested cell lines, illustrating its potency in 
various cancer types (Figure 9). 
 
Fig. 9 VioA inhibits proliferation in various cancer cell lines. Proliferative capacity of different 
cancer cell lines and corresponding IC50 values were determined by cell titer blue assay 
(suspension cell lines) or crystal violet staining (adherent cell lines) after 72h. Data points always 
represent the mean ± SEM of three independent experiments performed in triplicates. 
 
3.1.2 Impact of Vioprolide A on apoptosis and cell cycle progression 
To analyze whether enhanced cell death rates contribute to diminished proliferative 
capacity of VioA treated cancer cells, apoptosis assays were performed. Propidium iodide 
(PI) staining followed by flow cytometry was conducted according to Nicoletti et al. VioA 
exhibited an EC50 of 17.3 and 23.5 nM in CEM and Jurkat cells, respectively, signifying a 
relatively high apoptotic rate in acute lymphoblastic leukemia (ALL) cells (Figure 10A, C), 
compared to the AML cell line HL-60 and the solid cancer cell lines HeLa and T24 
(Figure 10B, C). The induction of apoptotic cell death was furthermore verified by 
caspase-3 (CASP3) and caspase-8 (CASP8) activation and the cleavage of the enzyme 
poly ADP ribose polymerase (PARP), analyzed by western blot (Figure 8D).  
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Fig. 10 Apoptosis induction in various cancer cell lines. Apoptosis of (A) Jurkat and CEM cells 
as well as (B) HL-60, T24 and HeLa cells treated with VioA for 24h. Percentage of apoptotic cells 
was determined by propidium iodide staining and flow cytometry. Data points always represent the 
mean ± SEM of three independent experiments performed in triplicates. (C) Corresponding EC50 
values. (D) Confirmation of VioA induced apoptotic cell death by western blot analysis of caspase 
activation and poly ADP ribose polymerase (PARP) cleavage. Jurkat and CEM cells were treated 
with VioA for 24h and protein levels of procaspase-3 (CASP3), procaspase-8 (CASP8) and 
cleavage of PARP were determined. Representative blots out of three independent experiments 
are shown. 
 
To confirm the potency of VioA in ALL and to analyze its putative therapeutic relevance, 
the compound was subsequently tested in ALL patient derived xenograft (PDX) cells.  In 
accordance with previous cell culture experiments, VioA treated ALL samples of diverse 
background (see section 2.1.1.2) generally showed an increased apoptosis rate after 24h 
treatment compared to DMSO control as shown by flow cytometry. Notably, peripheral 
blood mononuclear cells (PBMCs) of healthy donors barely responded to VioA compared 
to PDX samples (Figure 11). 
D C 
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Fig. 11 VioA induces apoptosis in PDX cells. ALL PDX cells of diverse background and PBMCs 
treated with VioA for 24h. Percentage of apoptotic cells was determined by flow cytometry and 
specific apoptosis was calculated towards DMSO control. Data points represent independent 
experiments (PDX cells: n=2, PBMC: n=3) performed in triplicates, one-way ANOVA, Dunnett’s 
test, * P<0.033, *** P<0.001, **** P<0.0001. 
 
Of a wide range of stimuli and conditions that can trigger apoptosis in cells, there are two 
main pathways to distinguish: the intrinsic (mitochondria mediated) and the extrinsic 
(death receptor mediated) pathway. To decipher which pathway is addressed by VioA 
treatment, characteristics of mitochondria mediated apoptosis were examined in VioA 
treated Jurkat cells. Mitochondrial membrane permeabilization is considered to be a 
general attribute of mitochondria mediated cell death and represented as a “point of no 
return” event resulting in apoptosis. Under physiological conditions, mitochondria display a 
high mitochondrial membrane potential (Δᴪm) while in cells undergoing apoptosis Δᴪm is 
dissipating (61). Thereby, the pro-apoptotic Bcl-2 family members BAX and BAK are 
recruited to the outer mitochondrial membrane (OMM) and oligomerize to mediate 
mitochondrial outer membrane permeabilization (MOMP), resulting in cytochrome C 
release and caspase activation (42). 
Here, we used the lipophilic cationic molecular probe JC-1 to measure the alterations of 
Δᴪm in VioA treated cells as the dye exhibits Δᴪm dependent aggregation. Of note, loss 
of Δᴪm could be demonstrated by decreased red/ green fluorescence ratio in VioA treated 
Jurkat cells after 24h (Figure 12A). Moreover, VioA strikingly downregulated the 
expression levels of antiapoptotic Bcl-2 family proteins Bcl-2, Bcl-xL and Mcl-1 after 24h 
treatment (Figure 12B). To further test the role of anti-apoptotic Bcl-2 family members on 
VioA- induced apoptosis, Bcl-2 and Bcl-xL overexpressing Jurkat cells (Figure 12C) were 
challenged with VioA. Additionally, a Jurkat cell line deficient for caspase-8 (Figure 12C) 
was tested. Caspase-8 plays a role in the extrinsic apoptotic pathway execution that is, 
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independently from the intrinsic pathway, activated upon death ligand (e.g. FasL) binding 
to death receptors and receptor ligation (62). Jurkat cells overexpressing Bcl-2 or Bcl-xL 
were significantly less sensitive towards VioA treatment than the empty vector control cell 
line Jurkat neo, whereas Jurkat Casp8 -/- exposed a sensitivity towards VioA equally to 
Jurkat neo (Figure 12D-E). These results indicate that apoptosis induction by VioA can 
only be effectively executed upon functional mitochondrial apoptosis signalling and that 
the extrinsic pathway does not contribute to VioA induced apoptosis. 
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Fig. 12  Vioprolide A causes mitochondria mediated apoptosis. (A) JC-1 was used as 
fluorescent probe for cytometric determination of mitochondrial membrane potential (Δϕm) in Jurkat 
cells treated with VioA as indicated for 24h. The green fluorescent JC-1 monomer population 
represents cells with loss of Δϕm and was quantitatively measured by flow cytometry. Bars 
represent the mean ± SEM of three independent experiments performed in triplicates, one-way 
ANOVA, Dunnett’s multiple comparisons test, *** P<0.001. (B) Expression levels of the anti-
apoptotic mitochondrial proteins Bcl-2, Bcl-xL and Mcl-1 decline upon VioA treatment as indicated 
for 24h. (C) Verification of Bcl-2 and Bcl-xL overexpression as well as caspase-8 deficiency by 
western blot. (D) Apoptosis induction is suppressed in Bcl-2 and Bcl-xL overexpressing Jurkat cells 
respectively (Jurkat Bcl-2, Jurkat-Bcl-xL) compared to the empty vector control cell line (Jurkat 
neo). Caspase-8 deficiency (CASP8 -/-) does not rescue Jurkat cells from apoptosis induction by 
VioA. Percentage of apoptotic cells was determined by propidium iodide staining and flow 
cytometry after 24 h. Bars always show the mean ± SEM of three independent experiments 
performed in triplicates, two-tailed unpaired Student’s t-test, ** P<0.002, *** P<0.001. (E) Induction 
of apoptosis analyzed by immunoblotting. Jurkat cells were treated with VioA as indicated for 24h 
and protein levels of caspase-3 (CASP3), caspase-8 (CASP8) and poly ADP ribose polymerase 
(PARP) were determined. (B, C, E) Representative blots out of three independent experiments are 
shown. 
B 
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Analysis of cell cycle progression in Jurkat cells treated with VioA for 24h furthermore 
revealed a significant decrease of cells in S-phase and an increased proportion of cells in 
G1, which was measured by propidium iodide staining followed by flow cytometry 
(Figure 13). 
 
Fig. 13 Influence of VioA on cell cycle progression of Jurkat cells. Cell cycle analysis of Jurkat 
cells treated with VioA as indicated for 24h. Cellular DNA content was determined by propidium 
iodide (PI) staining and flow cytometry. Proportion of cells in different stages of the cell cycle was 
calculated with the cell cycle tool provided by FlowJo software. Bars always represent the mean ± 
SEM of three independent experiments performed in triplicates, one-way ANOVA, Dunnett’s 
multiple comparisons test, * P<0.033, ** P<0.002, *** P<0.001, **** P<0.0001. 
 
3.1.3 Vioprolide A reduces cancer cell migration and invasion 
Besides extensive cell growth, metastasis of primary cancer cells to distant organs is a 
major challenge in the management of tumors. For this reason, the ability of VioA to inhibit 
the migratory and invasive potential of the metastatic cancer cell line T24 was investigated 
using a transwell migration assay and a spheroid based invasion assay, respectively. 
In a Boyden chamber assay, cells were allowed to migrate through transwell 8µm pores 
towards a chemoattractant and migratory cells were stained and counted after 16h 
(Figure 14). At subtoxic concentrations, VioA significantly reduced the migration capacity 
of the highly invasive bladder carcinoma cell line T24.  
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Fig. 14 Anti-migratory effects of Vioprolide A. (A) Representative images of Boyden chamber 
inserts. (B) Quantification of migrated cells was performed with ImageJ software. Bar diagram 
showing the number of migrated cells as mean ± SEM of three independent experiments after 
normalisation to DMSO control (ctrl), one-way ANOVA, Dunnett’s test, * P<0.033, ** P<0.002. 
Invasion into healthy surrounding tissues is generally considered as a hallmark of cancer 
(45). To determine the invasiveness of VioA treated cells, a three-dimensional (3D) 
spheroid assay was performed. The major advantage provided by 3D spheroid assays is 
that tumor cells are organized in a 3D structure, mimicking a solid tumor 
microenvironment. Hence, cells within a spheroid are challenged with tumor-like harsh 
conditions like hypoxia or nutrient deprivation, changing gene expression that can 
promote migration and invasion (57). As shown in Figure 15, VioA dose-dependently 
decreased T24 spheroid cell invasion into surrounding matrix (Matrigel™), which was 
monitored over a time-period of 72h. 
 
Fig. 15 Reduction of T24 spheroid invasion. Spheroids were generated by seeding T24 cell 
suspension into ultra-low attachment plates and were allowed to grow for 48h before embedding 
into Matrigel™ and treatment with VioA as indicated. Pictures were taken 24h, 48h and 72h after 
embedding. (A) Representative pictures out of three independent experiments performed in 
triplicates are shown. (B) Quantification of invasion with the ImageJ confluence application 
normalized to day 0. Data points represent the mean ± SEM of three independent experiments 
performed in triplicates. 
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3.2 Target identification via thermal proteome profiling 
To elucidate the molecular mechanism underlying the potent biological activity of the 
natural compound VioA, target identification was performed. Thermal proteome profiling 
(TPP) was thereby chosen as modification-independent strategy of the complex natural 
product. TPP works in living cells by determining stabilizing effects on proteins upon 
compound binding at elevated temperatures (63-65). Sample preparation, MS analysis as 
well as data processing were performed as described in section 2.11 by Volker Kirsch 
(group of Prof. Stefan Sieber, TU Munich, Germany).  
 
In detail, Jurkat cells were incubated with VioA (1µM) or DMSO and were subsequently 
exposed to a range of temperature points between 37°C and 67°C. Cells were lysed, 
soluble proteins isolated by ultracentrifugation; tryptically digested and labelled using 
isobaric tandem mass tag labels (TMT). Respective labelled samples were combined, 
subjected to hydrophilic-interaction chromatography (HILIC) fractionation and finally 
analyzed by LC-MS/MS (Figure). After filtering, Tm shifts that were calculated from two 
replicates of VioA versus DMSO treatment were visualized (Figure S1). All hits (proteins 
with a temperature shift of minimum 1°C in both biological replicates) were manually 
inspected and 67 proteins exhibited proper melting curves.  
U2 snRNP-associated SURP motif-containing protein (U2SURP) and nucleolar protein 14 
(NOP14) pertained as highly stabilized upon VioA treatment (Figure 16). NOP14, which is 
showing the highest stabilization, is crucial for ribosome biosynthesis. Ribosome 
biogenesis displays an essential process for cancer cell growth and could therefore be 
considered as plausible target of a cytotoxic compound like VioA. Consequently, NOP14 
was selected for in-depth validation. 
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Fig. 16 Target identification of VioA in Jurkat cells using thermal proteome profiling. 
(A) Schematic workflow of thermal proteome profiling experiment. Intact Jurkat cells were treated 
with 1µM VioA or DMSO respectively for 1h to ensure compound-target engagement. 
Subsequently, aliquots were incubated at 9 different temperature points (37°C – 67°C), centrifuged, 
proteins in supernatant digested, TMT-labelled, HILIC fractionated and analyzed by mass 
spectrometry. (B) Scatter plot of Tm shifts calculated from two biological replicates of VioA vs. 
DMSO treatment. Melting point shifts passing all significance criteria (Table S1) are shown in blue. 
Data were processed using MaxQuant and thermal response curve fitting as well as melting point 
calculation was carried out using the TPP TR R package. (C) Thermal response curves for NOP14 
and U2SURP proteins of VioA treated (orange) and DMSO (grey) treated cells. TPP experiment 
was carried out in two independent replicates. Experiment was performed by Volker Kirsch in the 
laboratory of Prof. Dr. Stephan Sieber (TU Munich, Germany). 
 
3.3 Target verification 
3.3.1 Inhibition of rRNA production without nucleolar disassembly 
The nucleolar protein 14 (NOP14) is crucial for the biosynthesis of new ribosomes, playing 
a significant role in 40S ribosome subunit formation as well as maturation of 18S rRNA 
(66). In eukaryotes the first step of ribosome biogenesis takes place in the nucleoli, where 
ribosomal DNA transcription by DNA polymerase I (Pol I) occurs. Ribosomal DNA 
encodes for ribosomal RNA (rRNA), which in turn builds the nucleic acid backbone of the 
ribosome (29). In NOP14 siRNA knockdown cells, rRNA levels in nucleoli as visualized by 
5-Fluorouracil (5-FU) incorporation, immunostaining and confocal microscopy were 
significantly lower compared to non targeted (nt) control cells (Figure 17A). Interestingly, 
VioA treated cells as well exhibited decreased rRNA levels compared to DMSO-treated 
control cells, suggesting an equivalent effect (Figure 17B). Actinomycin D (ActD), which 
intercalates into GC-rich duplex-DNA, thereby inhibiting Pol I transcription served as a 
positive control for blocked rRNA production (Figure 17B).  
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Fig. 17 Inhibition of rRNA production by NOP14 silencing and VioA treatment. (A) Nuclear 
run on assay with HeLa cells transfected with non targeting (nt) or NOP14 siRNA for 48h. Cells 
with nucleolar rRNA foci were counted as rRNA producing cells and values were normalized 
towards control. (B) Nuclear run on assay with HeLa cells treated either with VioA for 24h or with 
6µM Actinomycin D (ActD) for 2h, which served as positive control. Cells with nucleolar rRNA foci 
were counted as rRNA producing cells. Bars represent the proportion of cells with rRNA foci as 
mean ± SEM of three independent experiments, two-tailed unpaired Student’s t-test, *** P<0.001 
(A), one-way ANOVA, Dunnett’s multiple comparisons test, ** P<0.002 (B). 
 
Moreover, ongoing rDNA transcription is necessary for the formation of nucleoli, whereas 
perturbations of the transcriptional machinery lead to their rapid disassembly (26). 
Consistently, ActD treatment led to distribution of the nucleolar protein NOP14 in the 
whole nucleus due to nucleolar disruption, subsequently to Pol I transcription inhibition. 
VioA treatment however, revealed no alterations in nucleolar morphology and localization 
as visualized by NOP14 immunostaining (Figure 18). These results indicate that VioA 
does not interfere with ribosome biogenesis at the level of transcription. 
 
Fig. 18 Nucleoli remain intact upon VioA treatment. HeLa cells treated with 10nM VioA for 24h 
or 6µM ActD for 2h and immunostained for NOP14. Nuclei were visualized by Hoechst 33342 
staining. Representative images out of three independent experiments are shown. 
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3.3.2 Expression of NOP14 in different cell types 
Ribosome biogenesis is enhanced in cancer cells due to their high demand of continuous 
ribosome production for extensive cell growth (26, 28). A comparison of NOP14 
expression levels in various cancer cell lines, an ALL PDX cell sample and PBMCs of 
healthy donors revealed that ALL cell lines Jurkat and CEM, as well as the tested PDX 
cells feature high endogenous NOP14 levels in contrast to HL-60 cells (Figure 19). Of 
note, also PBMCs revealed lower NOP14 protein levels, suggesting a possible correlation 
between sensitivity of cells towards VioA induced apoptosis and NOP14 expression.  
 
Fig. 19 NOP14 protein expression in various cancer cell lines. Basal expression of NOP14 in 
different leukemia and solid cancer cell lines and PBMCs of healthy donors was investigated by 
immunoblotting. Actin served as loading control. Representative blot out of three independent 
experiments is shown. 
 
3.3.3 NOP14 plays a role in cancer cell growth 
To elucidate if there is a functional link between the vast growth inhibitory and apoptosis 
inducing effects of VioA and its potential target NOP14, proliferation and apoptosis assays 
were conducted after successfully knocking down NOP14 in HeLa cells using siRNA 
(Figure 20E). Proliferation was clearly diminished in NOP14 siRNA treated HeLa cells 
compared to non-targeted (nt) control cells, as displayed by increased doubling time 
values (nt ctrl: 33h, siNOP14 62h) (Figure 20A). These results provide evidence that the 
growth inhibitory effect of VioA is mainly mediated by NOP14. Conversely, silencing of 
NOP14 did not induce apoptotic cell death in HeLa cells (Figure 20B-C). Additional VioA 
treatment of siRNA transfected HeLa cells displayed a slightly increased apoptosis rate in 
NOP14 silenced cells compared to nt control cells (Figure 20D).  
3. Results Part I - Vioprolide A 
54 
 
A 
D 
B C 
 
Fig. 20 Functional link between NOP14 and anticancer effects of VioA. (A) xCELLigence real-
time proliferation measurement of HeLa cells either transfected with nt or NOP14 siRNA for 24h 
before seeding into E-plates. Proliferation was monitored for the subsequent 72h. Representative 
curve out of three independent experiments is shown. Respective doubling time values were 
calculated using xCELLigence RTCA software. Bars represent the mean ± SEM of three 
independent experiments, two-tailed unpaired Student’s t-test, ** P<0.002. (B) Nicoletti apoptosis 
assay of HeLa cells either transfected with nt or NOP14 siRNA for the indicated time points. Bars 
represent the mean ± SEM of three independent experiments performed in triplicates. (C) Induction 
of apoptosis analyzed by immunoblotting. Jurkat cells were treated with VioA as indicated for 24h 
and protein levels of caspase-3 (CASP3) and poly ADP ribose polymerase (PARP) were 
determined. (D) Nicoletti apoptosis assay of HeLa cells either transfected with nt or NOP14 siRNA 
for 24h before stimulation with VioA for further 24h. Bars represent the mean ± SEM of three 
independent experiments performed in triplicates. (E) Verification of NOP14 siRNA knockdown by 
western blot analysis. 
E 
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3.4 Target interactome analysis 
3.4.1 Pulldown of NOP14 interactome 
Previous studies in yeast showed that various protein-protein interactions with NOP14 are 
essential for a proper working ribosome biogenesis machinery (67). Thus, we further 
focused on unravelling the interactome of NOP14 in the human cell line Jurkat via MS-
based co-immunoprecipitation (co-IP) experiments. MS-based co-IP was conducted via 
an immobilized anti-NOP14 antibody in presence of DSSO as crosslinker to enable also 
temporal binding partners being trapped as applied previously (Figure 21) (68). MS-based 
co-IP experiments were conducted by Volker Kirsch in the laboratory of Prof. Dr. Stephan 
Sieber (TU Munich, Germany). 
 
Fig. 21 Schematic workflow of MS-based co-immunoprecipitation. Living cells were either 
treated with 10 nM VioA or DMSO, respectively, for 24 hours. Subsequently, DSSO linker was 
added to ensure covalent linkage of protein complexes within cells. NOP14 and linked interacting 
proteins were enriched using an anti-NOP14 antibody immobilized on protein A/G beads. Tryptic 
peptides were analyzed via LC-MS/MS. Experiments were performed by Volker Kirsch in the 
laboratory of Prof. Dr. Stephan Sieber (TU Munich, Germany). 
Analysis of pulled-down proteins via LC-MS/MS identified several highly enriched proteins 
compared to normal rabbit isotype control co-IP in Jurkat cells (Table S2), amongst 
others: the nucleolar complex protein 4 homolog (NOC4L) and the ribosomal RNA small 
subunit methyltransferase NEP1 (EMG1) (Figure 22). By now, detailed studies on the 
interactions between the yeast homologues of NOP14 and EMG1 (66) as well as NOC4L 
(69) revealed that physical interplay with both proteins is essential for proper maturation of 
18S rRNA and 40S assembly and export. 
 
 
3. Results Part I - Vioprolide A 
56 
 
 
Fig. 22 MS-based co-IP with NOP14 antibody. Volcano plot represents two-sample t-test results 
of anti-NOP14 co-IP compared to isotype control co-IP (n=4). Cutoff criteria were defined as log2 = 
2 (4-fold enrichment) enrichment factor and -log10 (t-test p-value) = 1.3 (dotted lines). NOP14 is 
colored in blue, NOC4L in dark grey and EMG1 in red. Experiments were performed by Volker 
Kirsch in the laboratory of Prof. Dr. Stephan Sieber (TU Munich, Germany). 
3.4.2 Selective inhibition of NOP14-EMG1 interaction 
In order to identify VioA susceptible interactions, a western blot based co-IP without 
crosslinking was performed with compound vs. vehicle treatment for 24h prior to NOP14 
pulldown. Stimulation with VioA led to a significant depletion of the NOP14-EMG1 
interaction (Figure 23A). Remarkably, the interaction between NOP14 and NOC4L 
remained unperturbed upon VioA treatment, indicating a selective inhibition of the NOP14-
EMG1 interface (Figure 23A). Of note, the endogenous expression levels of NOP14, 
NOC4L and EMG1 remained unaffected (Figure 23B), further signifying that reduced 
EMG1 levels in western blot based co-IP are result of reduced physical interplay between 
NOP14 and EMG1.  
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Fig. 23 VioA disrupts NOP14-EMG1 interaction without influencing respective endogenous 
protein levels. (A) Co-IP of NOP14 in Jurkat cells and detection of NOP14 and interaction 
partners NOC4L/ EMG1 by western blot analysis. A representative experiment out of three 
independent experiments is shown. Bars represent the mean ± SEM of three independent 
experiments, two-tailed unpaired Student’s t test, *** P<0.001. (B) Western blot analysis of NOP14, 
NOC4L and EMG1 expression levels of Jurkat cells either treated with DMSO or 10nM VioA, 
respectively for 24h. Bars represent the mean ± SEM of three independent experiments, two-tailed 
unpaired Student’s t test, ns P>0.05. 
 
According to literature, the NOP14-NOC4L complex is required for the nucleolar 
localization of NOP14 (69). Immunostaining of HeLa cells treated with VioA revealed that 
NOP14 maintains its nucleolar localization also upon VioA stimulation (Figure 24), further 
substantiating that the heterocomplex NOP14-NOC4L pertains upon treatment. By 
contrast, treatment of VioA led to an increased amount of EMG1 in the cytoplasm, 
whereas in DMSO treated cells EMG1 is mainly located in the nucleus. This observation is 
in line with previous studies, stating that NOP14 is required for nuclear localization of 
EMG1 (66).  To furthermore check if the EMG1 delocalization is a possible general effect 
upon ribosome biogenesis inhibition, HeLa cells were stimulated with Doxorubicin (Doxo), 
inhibiting ribosome biogenesis by interfering with Pol I transcription. As it was to be 
expected, NOP14 lost its nucleolar localization because of nucleolar disintegration upon 
Doxo stimulation (Figure 24). Conversely, also in Doxo treated cells, EMG1 was mainly 
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localized in the nucleus, excluding a general effect of ribosome biogenesis inhibition on 
EMG1 delocalization. 
 
Fig. 24 VioA causes delocalization of EMG1. HeLa cells treated with 10nM VioA for 24h or 
250nM Doxorubicin (Doxo) for 2h were co-stained for NOP14 (red) and EMG1 (green). Nuclei were 
stained with Hoechst 33342. Representative images out of three independent experiments 
performed in duplicates are shown. 
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3.5 Summary 
In summary, vioprolides represent a unique class of natural compounds with potent 
bioactivity towards cancer cells in the nanomolar range. ALL cancer cells showed high 
sensitivity towards VioA apoptosis induction, in contrast to PBMCs, introducing VioA as 
promising lead structure for cancer cell targeting. By applying TPP as target identification 
approach in cooperation with the group of Prof. Sieber (TU Munich, Germany), we were 
able to identify nucleolar protein 14 (NOP14), as interaction partner of VioA. NOP14 plays 
a key role in ribosome biogenesis, more precisely, the assembly and export of the small 
ribosomal subunit. Remarkably, VioA represents the first small molecule addressing this 
pathway. Of note, NOP14 was found highly expressed in ALL in contrast to PBMCs, 
offering a prospective for a selective therapeutic approach. Closer mechanistic studies 
furthermore revealed that VioA alters the interaction of NOP14 with EMG1. Our study 
highlights the potential of targeting the NOP14-EMG1 interface, and thereby ribosome 
biogenesis, as a promising anticancer strategy and underlines the great capability of VioA 
as biochemical tool in cancer research, as well as for future drug development. 
  
Fig. 25 Vioprolide A project summary. 
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4. Results Part II - Lagunamide A 
4.1 Anticancer effects of Lagunamide A 
4.1.1 Antiproliferative and apoptosis inducing effects of LagA 
LagA exhibited strong growth inhibitory effects in the human pancreatic cell lines (BxPC3, 
Panc 03.27 and Panc 10.05) and the human cervical carcinoma cell line HeLa, with IC50 
values in the nanomolar range (Figure 26A). As all tested cell types visibly showed 
cytotoxic phenotypes at higher concentrations, induction of apoptotic cell death was 
subsequently quantified. Incubation with LagA for 48h resulted in strong apoptosis 
induction in pancreatic and cervical carcinoma cells with EC50 values between 27.2 and 
40.9nM (Figure 26B). 
 
Fig. 26 Evaluation of cytostatic and apoptosis inducing effects of LagA in pancreatic and 
cervical carcinoma cells.  (A) Proliferative capacity of different cancer cell lines and 
corresponding IC50 values were determined by crystal violet staining after 72h. (B) Apoptotic effect 
of LagA on different cancer cell types. Percentage of apoptotic cells and respective EC50 values 
were determined by propidium iodide staining and flow cytometry after 48h. Results are presented 
as mean ± SEM of three independent experiments performed in triplicates. 
 
4.1.2 Inhibition of migration 
By using the RTCA xCELLigence system, the effect of LagA on tumor cell migration was 
investigated in BxPC3 and HeLa cells, respectively. This impedance-based method allows 
real-time monitoring of cells migrating through an 8µm porous membrane towards a 
chemoattractant. Representative curves are shown in Figure 27. The cell index, which is 
proportional to the number of migrating cells, is decreasing dose-dependently upon LagA 
treatment applied in subtoxic doses. Migration inhibition in both cell types was additionally 
quantified over a time-period of 16h as shown in corresponding bar diagrams. 
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Fig. 27 Inhibitory effect of LagA on cancer cell migration. Real time monitoring of migration of 
(A) HeLa cells and (B) BxPC3 cells over 16h using the xCELLigence migration assay. Relative 
migration was calculated using RTCA software; representative curves out of three independent 
experiments are shown. Bars represent the mean ± SEM of three independent experiments 
performed in duplicates, one-way ANOVA, Dunnett’s multiple comparisons test, * P<0.033, 
** P<0.002, *** P<0.001, **** P<0.0001. 
 
4.2 Effects of Lagunamide A on mitochondria 
4.2.1 Lagunamide A alters mitochondrial morphology and dynamics 
Based on the fact that LagA is structurally related to Aurilide, shown to target 
mitochondrial pathways (70), we focused on mitochondria for further functional 
characterization of LagA. To analyze mitochondrial morphology in response to LagA 
treatment, transmission electron microscopy (TEM) was performed by Dr. Sabine Schmitt 
and Carola Eberhagen in the laboratory of Prof. Dr. Hans Zischka (Helmholtz Centre 
Munich, Germany). As shown in Figure 28A, mitochondria of control cells are structurally 
intact and reveal a clearly recognizable cristae structure. In HeLa cells treated with 150nM 
LagA for 30 min, mitochondria show the same characteristics like control cells, but are in 
total slightly smaller. By contrast, 10nM LagA treatment for 24h resulted in significantly 
smaller mitochondria with an extremely condensed matrix. Of note, mitochondria are still 
undamaged, meaning that there is no swelling or rupture of the outer membrane 
detectable. Furthermore, mitochondrial cristae are still apparent, but extremely enlarged. 
B 
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To further investigate mitochondrial fission and fusion dynamics in LagA treated cells, live 
cell imaging of HeLa cells was performed subsequently to MitoTracker® Green FM 
staining. As it is shown in Figure 28B, stimulation with LagA led to a significant impairment 
of mitochondrial dynamics accompanied by increased fission. To ensure that the applied 
conditions are subtoxic, cell death rates were measured in parallel by PI staining and flow 
cytometry (Figure 28C). 
 
 
Fig. 28 Effects of LagA on mitochondrial morphology and dynamics in HeLa cells. (A) 
Transmission electron microscopy of HeLa cells treated with LagA as indicated. Electron 
microscopy was performed by Dr. Sabine Schmitt and Carola Eberhagen in the laboratory of Prof. 
Dr. Hans Zischka (Helmholtz Centre Munich, Germany). (B) Live cell imaging of HeLa cells 
subjected to 150nM LagA. Cells were stimulated with LagA at t = 18 min. Mitochondrial structures 
were visualized with MitoTracker® Green FM dye. (C) Applied concentrations are subtoxic. HeLa 
cells were treated with LagA as indicated and cell death quantification was conducted by propidium 
iodide staining and flow cytometry. (A, B) Representative images out of three independent 
experiments are shown. (C) Bars represent the mean ± SEM of three independent experiments 
performed in triplicates. 
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4.2.2 Mitochondrial mass decreases upon LagA treatment 
As a further parameter of mitochondrial health, changes in mitochondrial mass of LagA 
treated cells were determined by MitoTracker® Green FM staining followed by flow 
cytometry. MitoTracker® Green FM is able to stain mitochondria in a manner that is 
independent of their membrane potential, consequently providing a readout relating solely 
to mitochondrial mass (71). As shown in Figure 29A, treatment with low doses of LagA for 
24h led to reductions of mitochondrial mass levels. Interestingly, LagA 150nM treatment 
for 5-30 min resulted in noticeably decreased MitoTracker® Green fluorescence, 
indicating that LagA triggers a rapid and direct effect on mitochondria. Subsequently, 
expression levels of a key regulator of mitochondrial biogenesis, peroxisome proliferator-
activated receptor-γ coactivator (PGC)-1α (72), in response to LagA treatment was 
investigated. PGC1α acts as a transcription factor coactivator, influencing a majority of 
cellular metabolic pathways and serving as a stress sensor in cancer cells in order to 
maintain metabolic homeostasis (73). However, LagA treatment did not alter expression 
levels of PGC1α, suggesting that this regulatory pathway is not addressed (Figure 29B). 
 
Fig. 29 Decrease of mitochondrial mass upon LagA treatment. (A) HeLa cells treated with 
LagA and subjected to MitoTracker® Green FM staining followed by flow cytometry. Bars represent 
the mean ± SEM of three independent experiments performed in triplicates, one-way ANOVA, 
Dunnett’s test, * P<0.033, *** P<0.001. (B) Western blot analysis of HeLa cells treated with LagA 
and probed with anti-PGC1α antibody. Representative blots of three independent experiments are 
shown. 
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4.2.3 Effects on mitochondrial function and bioenergetics 
Altered mitochondrial morphology and dynamics indicate that the potent anticancer 
properties of LagA might be derived from interference with mitochondrial activity. To 
further investigate the effect of LagA on mitochondrial function, we monitored cellular 
oxygen consumption rates (OCR) as measures of mitochondrial respiration using a 
Seahorse Extracellular Flux analyzer. In detail, the key parameters of mitochondrial 
function were determined by sequentially exposing cells to mitochondria perturbing 
reagents in the so called mitochondrial stress test (see section 2.11). After measuring 
basal respiration rates of HeLa cells pre-treated with subtoxic concentrations of LagA for 
24h, oligomycin, FCCP and a combination of rotenone and antimycin A were 
consecutively added. Real-time measurements of OCR are shown in Figure 30A and 
respective quantifications are shown in Figures 30B-G. As presented in Figure 30A and B, 
basal respiration is diminished by treatment with 10 nM LagA, suggesting a decrease in 
oxidative phosphorylation. Next, the ATP synthase inhibitor oligomycin was added, which 
was used here to distinguish between ATP-linked respiration and oxygen consumption 
that is used to overcome the proton leak across the mitochondrial membrane. 
Subsequently, addition of FCCP uncoupled oxygen consumption from ATP production by 
disrupting the mitochondrial membrane potential and raised OCR to a maximum value. 
Maximal respiration was, like basal respiration, reduced upon LagA treatment 
(Figure 30C). These results are also consistent with decreases in ATP-linked respiration 
(Figure 30D). By the final injection of Antimycin A (AntA) and rotenone the electron 
transport chain was targeted, thereby reducing OCR to a minimum value. Spare 
respiratory capacity represents the reserve capacity of a cell to generate ATP via 
oxidative phosphorylation in case of an increased demand for energy. Interestingly, this 
bioenergetics capacity of mitochondria was not altered in LagA treated cells compared to 
control cells (Figure 30E). Overall, the substantial decrease in OCR upon LagA treatment 
suggests that the natural product targets a critical pathway for oxidative phosphorylation 
(OXPHOS). However, since the addition of oligomycin resulted in a further decrease of 
OCR, it appears that LagA either has an incomplete effect or that a modulatory pathway is 
targeted.  
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Fig. 30 Decrease in oxygen consumption rate (OCR) in LagA treated cells. Seahorse mito 
stress test was performed to measure OCR in LagA treated HeLa cells following the sequential 
addition of inhibitors of mitochondrial function: oligomycin, FCCP, and a combination of rotenone 
and antimycin A. (A) Real-time OCR profile plot, (B) basal respiration, (C) maximal respiration, (D) 
ATP production and (E) Spare respiratory capacity, calculated based on the difference between 
basal and maximal respiration. (A) Representative plot of three independent experiments is shown. 
(B-E) Bars represent the mean ± SEM of three independent experiments performed in triplicates, 
one-way ANOVA, Dunnett’s multiple comparisons test, ** P<0.002, *** P<0.001. 
 
4.2.4 Impact on mitochondrial apoptotic cell death 
In addition to their role in cellular respiration, mitochondria play a key role in regulating 
apoptotic cell death. To provide insight into the mechanism of LagA induced cell death as 
shown in section 4.1.1 Figure 24B, critical markers of mitochondria-mediated apoptosis 
were investigated in different cell lines. Of note, LagA did not alter expression levels of the 
pro-apoptotic protein Bak, but markedly downregulated the expression levels of the 
antiapoptotic Bcl-2 family proteins Bcl-2, Bcl-xl and Mcl-1 in all testes cell types 
(Figure 31), providing evidence that LagA induces mitochondria mediated apoptosis.   
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Fig. 31 Induction of apoptosis analyzed by immunoblotting. BxPC3, Panc 03.27 and HeLa 
cells were treated with LagA as indicated for 48h and protein levels of Mcl-1, Bcl-2, Bcl-xl and Bak, 
as well as PARP cleavage were determined. Representative blots of three independent 
experiments are shown. 
 
4.3 Investigations on the molecular mechanism of action of 
Lagunamide A 
4.3.1 Effects on key mitochondrial fission and fusion regulators 
In view of the substantially altered mitochondrial dynamics and morphological changes in 
mitochondria of LagA treated cells, key players of mitochondrial fission and fusion were 
investigated, subsequently. Mitochondrial fusion is a complex sequential process, 
involving the integration of the outer mitochondrial membrane and the inner mitochondrial 
membrane (49). The main regulators of this process are the dynamin-related GTPase 
mitofusin 1 (Mfn-1), implicated in outer membrane fusion and optic atrophy 1 (OPA-1) that 
is anchored in the inner mitochondrial membrane (49, 50). Of note, LagA treatment of 
HeLa cells for 24h (Figure 32A) led to a significant decrease in endogenous levels of both 
OPA-1 and Mfn-1, being in line with the fragmented mitochondrial phenotype described in 
section 4.2.1. A slight decrease in Mfn-1 protein levels can also be observed in the high 
dose setting after 30 min. (Figure 30A) By contrast, LagA treatment did not alter Mfn-1 
expression in the pancreatic cancer cell lines BxPC3 and Panc 03.27. Furthermore, 
regarding the OPA-1 protein, only long isoforms levels were found down-regulated after 
LagA treatment. Panc 03.27 cells are KRAS mutated and the oncogenic protein RAS was 
previously described to induce mitochondrial fission via phosphorylation of dynamin-
related protein 1 (DRP1) at Ser616 (52). Taken this into consideration, the key 
mitochondrial fission regulator DRP1 was investigated in pancreatic cell lines by western 
blot analyses. Remarkably, LagA did neither alter DRP1 total levels nor the Ser616 
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phosphorylated form, which is implicated in mitochondrial fission. Conversely, 
phosphorylation of DRP1 at Ser637, which decreases GTPase activity and reduces 
mitochondrial fission, was found to be enhanced in LagA treated Panc 03.27 cells 
(Figure 32B).  By contrast, DRP1 seems not to be addressed in LagA treated BxPC3 cells 
(Figure 32B). Overall, these data suggest a cell line dependent cellular response to LagA 
treatment and underscores the complexity of mitochondrial dynamics in the context of 
cancer.  
 
Fig. 32 Differential regulation of key mitochondrial fission and fusion markers in LagA 
treated cells. (A) HeLa cells treated with LagA and subjected to western blot analysis for OPA-1 
and Mfn-1. (B) BxPC3 and Panc 03.27 cells treated with LagA and probed for OPA-1, Mfn-1, 
DRP1, p-DRP1 (Ser616) and p-DRP1 (Ser637) expression by western blot analysis. (A, B) 
Representative blots of three independent experiments are shown.  
 
4.3.2 Lagunamide A and Aurilde do not share protein targets 
Based on the fact that LagA and the marine cyclodepsipeptide Aurilide derived from 
Dolabella auricularia are very similar in structure (Figure 33A), we first hypothesized that 
their protein targets are identical. This was further encouraged by the fact that Aurilde as 
well as LagA exert potent cytotoxic effects and were shown to induce mitochondrial 
fragmentation and apoptosis (74). Sato et al. presented prohibitin 1 (Phb1) as molecular 
target of Aurilide and showed that binding to Phb1 disrupts the Phb1-spastic paraplegia 7 
(SPG7) interactions. Furthermore, they could demonstrate that Aurilide accelerates the 
proteolytic processing of optic atrophy 1 (OPA1) long isoforms to short isoforms, resulting 
in mitochondria mediated apoptosis (70). 
Consequently, to validate Phb1 as potential target of LagA, co-IP experiments of Phb1 
were performed to investigate the Phb1-SPG7 interaction. In contrast to Aurilide, LagA 
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was not able to perturb SPG7 binding to Phb1, suggesting that Aurilide and LagA trigger 
their biological effects via different target proteins (Figure 33B).  
 
 
 
Fig. 33 Lagunamide A and Aurilide do not share Phb1 protein target. (A) Chemical structures 
of LagA and Aurilide. (B) Western blot analysis for Phb1 and SPG7 of HeLa cells treated with 
10nM LagA for 24h (WB). Co-IP of Phb1 in HeLa cells and detection of Phb1 and interaction 
partner SPG7 by western blot analysis (Phb1 IP). One representative experiment out of three 
independent experiments is shown.  
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4.4 Summary 
In summary, LagA, a highly complex marine natural product, showe potent growth 
inhibitory and antimigratory potential in different cancer cell lines at nanomolar 
concentrations. Antiproliferative effects were additionally accompanied by mitochondria 
mediated apoptotic cell death. Subsequent functional characterization revealed changes 
in mitochondrial morphology, dynamics and oxygen consumption rates within nanomolar 
concentrations of LagA (Figure 34). These findings indicate a mitochondria-perturbing 
mode of action of the natural product and emphasize the need to elucidate the molecular 
target(s) addressed by this interesting molecule. As mitochondria have emerged as a 
potential target for anticancer therapy in recent years, LagA represents a promising new 
compound with potentially important applications as both anticancer drug lead structure 
and molecular probe to explore mitochondrial biology in cancer.  
 
Fig. 34 Lagunamide A project summary.  
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5. Discussion Part I  
5.1 Vioprolides as promising anticancer compounds 
Since the Vioprolides were introduced by Schummer et al. in 1996, no in-depth functional 
characterization or detailed studies concerning their molecular mode of action have been 
reported up to date. Encouraged by the potent anticancer activity of Vioprolides, which 
was claimed in the initial publication, we performed detailed analyses of their antitumor 
activities. Interestingly, Vioprolide A (VioA), which only differs in N-heterocycles compared 
to the other family members, had much greater growth-inhibitory efficacy against the 
tested cancer cell line Jurkat. These findings suggest that the heterocycles may play a 
particular role in interaction with the cellular target(s) of interest.  
Of note, VioA exhibited potent antiproliferative effects against a multitude of cancer cell 
types including leukemia, bladder cancer and cervical cancer. Additionally, VioA showed 
potent antimigratory potential and was effective in inhibiting invasion of T24 bladder 
carcinoma cells grown in three-dimensional culture. Furthermore, VioA demonstrated 
potent apoptosis inducing activity in various cancer cell lines with minimal effect in healthy 
PBMCs. This apoptosis inducing effect was particularly high in ALL cell lines and very 
importantly ALL patient derived xenograft cells of diverse background, highlighting a 
potential therapeutic relevance of VioA.  
In conclusion, we reinforced the potent structure-dependent antitumor effects of the 
Vioprolides. Furthermore, we identified VioA as the most promising derivative of this 
interesting natural compound class for subsequent detailed investigations. 
 
5.2 Targeting ribosome biogenesis as antitumor strategy 
Ribosome biogenesis is an essential process in every growing cell. In eukaryotes, this 
process is highly orchestrated, including the synthesis and processing of pre-ribosomal 
RNAs, ribosomal protein synthesis and finally assembly and export of the ribosomes.  
Moreover, these steps require hundreds of assembly factors, most of which are essential 
(75). It is not surprising that ribosome biogenesis is of particular importance for fast 
proliferating cells, highlighting that its inhibition is a well-founded strategy for anticancer 
treatment. One major advantage of selective inhibition of ribosomal biogenesis, in contrast 
to most currently used DNA damaging anticancer drugs, is the non-genotoxic inhibition of 
rRNA production by selectively interfering with polymerase I (Pol I) mediated rDNA 
transcription. Very importantly, ribosome biogenesis inhibitors are less efficient in resting 
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cells due to the long half-life of cytoplasmatic ribosomes (76), providing a basis for 
selective anticancer targeting. While several inhibitors of rRNA transcription have been 
reported (38, 39) and a number of established therapeutic drugs were shown to inhibit 
ribosome biogenesis at this level (37), no compounds are available that directly target the 
ribosome biogenesis pathway downstream of transcription. Moreover, an expanding body 
of evidence displays that also ribosome assembly is regulated by oncogenic signalling 
pathways (30), highlighting that there is a large repertoire of potentially new and 
innovative anticancer drug targets, besides Pol I transcription inhibition.  
 
5.2.1 NOP14 as novel druggable anticancer target 
Within the framework of this thesis, we present the nucleolar protein 14 (NOP14) as novel 
druggable anticancer target. Thermal proteome profiling as target identification approach 
identified NOP14 as direct target of VioA. Interestingly, siRNA knockdown studies 
confirmed that NOP14 plays a role in tumor cell growth, substantiating that VioA triggers 
its potent antiproliferative effects via targeting NOP14. Of note, previous literature data 
showed that there is an association between NOP14 overexpression in pancreatic cancer 
and tumor cell invasion (77, 78), being additionally in line with the strong antimigratory and 
antiinvasive effects we observed upon VioA treatment. However, the apoptosis inducing 
effect of VioA could not be attributed to NOP14 in siRNA knockdown studies. It must be 
noted that, due to technical reasons, silencing experiments were performed in HeLa cells, 
which are less sensitive towards VioA induced apoptosis, anyway. Hence, NOP14 
silencing experiments in cell types susceptible to VioA apoptosis induction, like the ALL 
cell lines Jurkat and CEM, will have to be done to provide a reasonable functional link 
between NOP14 and VioA induced apoptosis induction. In this context, also the high 
expression of NOP14 in ALL cell lines in contrast to healthy PBMCs is noteworthy. This 
finding suggests a putative correlation between NOP14 expression and susceptibility 
towards cell death induction and a clinical significance of NOP14. However, a substantial 
increase in the number of samples is needed to accurately evaluate whether NOP14 
expression is significantly correlated with the development of acute lymphoblastic 
leukemia in future studies. 
NOP14 plays a crucial role in ribosome biogenesis, more precisely the maturation of the 
18S rRNA and assembly of the 40S subunit. In the yeast model, NOP14 was shown to 
interact with numerous proteins, essential for proper functional ribosome assembly 
machinery (66, 69). MS-based co-IP experiments identified a complex compilation of 
NOP14 interaction partners. Strikingly, we could identify NOC4L and EMG1 as prominent 
binding partners of NOP14 in human cells. The yeast homologues of both proteins were 
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shown to be essential NOP14 interacting proteins (66, 69). Of note, western blot based 
co-IP confirmed that VioA selectively impairs the interaction between NOP14 and EMG1, 
whereas the NOP14-NOC4L complex remained unperturbed. Liu et al. showed that the 
interaction of NOP14 and EMG1 is essential for proper 18S rRNA maturation and 40S 
ribosome biogenesis in yeast (66), further underlining that VioA interferes with ribosome 
biosynthesis. Noteworthy, a single base mutation in EMG1 causes the highly lethal 
autosomal recessive disorder Bowen-Conradi syndrome, which is common in the Hutterite 
population (79, 80). Studies of Armistead et al. showed that this EMG1 mutation leads to 
an 18S rRNA processing delay, substantiating that the EMG1 function is conserved in 
yeast and human cells. More remarkably, they showed that proper levels of EMG1 are 
more critical in rapidly proliferating cells, such as lymphoblasts, than slower-growing cells 
like fibroblasts (81). These facts underscore the great potential of targeting the NOP14-
EMG1 complex, and thereby ribosome assembly as a selective approach in fast growing 
cells, such as in cancer.  
In summary, NOP14 was confirmed as promising therapeutic target for cancer treatment. 
Moreover, the identification of VioA as potent inhibitor of the NOP14-EMG1 interaction 
opens the door to explore upstream and downstream processes in depth. This could 
potentially provide additional therapeutic strategies for cancer patients and stimulate basic 
research in the topic ribosome assembly and cancer.  
 
5.2.2 Vioprolide A as the first compound targeting the ribosome assembly 
pathway 
The discovery of VioA as an inhibitor of the NOP14 dependent ribosome processing 
pathway substantiates the assumption that targeting the ribosome biogenesis pathway 
downstream of rDNA transcription is a promising anticancer strategy. Strikingly, VioA 
inhibited de novo rRNA synthesis, a crucial step in ribosome biogenesis. But, importantly, 
this effect was not accompanied by nucleolar disruption, which can be observed in cells 
treated with agents interfering with Pol I transcription, like ActD or Doxorubicin (35). These 
findings further confirm that VioA targets ribosome biogenesis via a unique mechanism. 
Production of ribosomes and protein synthesis are crucial processes for every growing 
cell, being in line with the antiproliferative effect of VioA. Furthermore, a proper functioning 
ribosome biosynthesis is necessary for cell cycle progression. Hence, the achievement of 
a sufficient ribosome amount during G1 phase, allows cells to overcome the G1-S 
restriction point (82). In accordance with these facts, VioA treatment led to a significant 
decrease of cells in S-phase and an increase of cells resting in G1. At higher VioA 
concentrations, cell cycle arrest was accompanied by induction of apoptotic cell death. 
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Interestingly, the extent of VioA exhibited apoptosis was cell-type specific, with ALL cells 
being the most sensitive candidates. Of note, Scala et al. also linked the inhibition of 
ribosome biogenesis to induction of apoptotic cell death. However, it was stated that only 
cancer cells with a high ribosomal biogenesis rate and thus dependence on this pathway 
are susceptible for apoptosis induction (83). In consequence, further investigations on 
differential ribosome biogenesis rates in cancer cells are needed to connect these findings 
with the sensitivity of ALL cells towards VioA.  
 
5.3 Future perspectives: Vioprolide A as chemical tool in human 
ribosome biogenesis and beyond 
The process of ribosome biogenesis has only been extensively studied in unicellular 
organisms, best described in the model organism Saccharomyces cerevisiae. While basic 
features of this pathway and many ribosomal proteins are conserved among eukaryotes, 
the human ribosome biogenesis pathway is considerably more complex due to increased 
size of human ribosomes, and a more complex regulatory network that modulates 
ribosome assembly and function (84). But, the high importance of uncovering the detailed 
ribosome assembly pathway in humans is emphasized by the fact that there is a growing 
number of ribosomopathies, caused by mutations in genes encoding ribosomal proteins or 
ribosome biogenesis factors (85, 86). Moreover, it has been shown that syndromes like 
Diamond-Blackfan anaemia, involving mutant ribosomal or nucleolar proteins are 
associated with an increased risk of cancer (87, 88).  
Additionally, ribosome biogenesis is tightly linked with numerous other pathways, like 
translational regulation. Translation itself has long been considered as housekeeping 
function. However, recent studies suggest that ribosomes also function as regulatory 
elements in translation (89). Mills and Green proposed that changes in cellular ribosome 
abundance may be a major driver of changes in translation of mRNA. In detail, ribosomes 
have different affinities for mRNAs. Hence, low-affinity mRNAs cannot compete with high-
affinity mRNAs when ribosomes are limited (86). These implications may also play a 
critical role in cancer, as altered ribosomal activity and selection of specific cancer-
associated mRNAs for translation have already been described (90, 91). 
Therefore, identification of novel factors involved in ribosome biogenesis and the 
investigation of the exact mechanisms by which such proteins alter tumor susceptibility is 
crucial. This highlights the need to establish inhibitors of the ribosome assembly pathway 
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to identify such key players and their regulatory network - not only to provide new 
strategies against related diseases, like cancer.  
With VioA targeting the NOP14-EMG1 complex, we discovered a new druggable step of 
the highly complex human ribosome assembly pathway. By introducing the molecular 
mode of action of VioA, a promising starting point is set to study this essential and 
disease-related pathway in depth by chemical inhibition.   
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6. Discussion Part II  
6.1 Targeting mitochondria as powerful approach in cancer 
therapy 
In recent years, mitochondria have emerged as potential anticancer targets as cancer cell 
mitochondria are structurally and functionally different from their non-cancerous 
counterparts (92). In this line, it is now recognized that the mitochondrial dynamics not 
only enable cells to meet metabolic requirements, but emerged as regulators of tumor 
growth, providing a basis for tumor targeting. In the context of this thesis, the marine 
natural compound Lagunamide A (LagA) was characterized as mitochondria-perturbing 
agent with striking effects on mitochondrial dynamics. 
6.1.1 Lagunamide A as an anticancer drug targeting mitochondrial dynamics 
Mitochondria are extremely dynamic organelles that constantly fuse and divide. Under 
physiological conditions, the mitochondrial network undergoes moderate fission and 
fusion, in order to fill the requirements for cellular metabolism (50). Mild levels of 
mitochondrial fission facilitate the autophagic clearance of mitochondria, whereas 
moderate levels of mitochondrial fusion provides the energy for communication between 
the mitochondrial networks (49). Moreover, previous studies have identified mitochondrial 
fission as the apoptotic trigger in various disease models (93, 94) . Thereby, mitochondrial 
fission has been acknowledged as a potential target to reduce the proliferation, migration 
and survival of cancer cells (95). Interestingly, mitochondria of LagA treated cells 
manifested obvious morphological changes from the normal fused to a fragmented shape. 
In accordance with previous findings, LagA had a striking impact on tumor cell 
proliferation, migration and induction of apoptotic cell death. The fragmented 
mitochondrial phenotype was furthermore accompanied by downregulation of the key 
mitochondrial fusion regulators, optic atrophy 1 (OPA-1) and mitofusin-1 (Mfn1), indicating 
a disruption of the mitochondrial fusion machinery by LagA. The fusion protein OPA-1 also 
regulates the formation of mitochondrial cristae, reflecting the enlarged cristae structure 
observed in mitochondria of LagA treated cells. These results provide evidence that LagA 
triggers its potent anticancer effects via induction of mitochondrial fission.  
Furthermore, mitochondrial dynamics are tightly linked to cellular metabolism. Cells 
lacking Mfn-1 and exhibiting a fragmented phenotype are associated with reduced 
mitochondrial respiration (96). Furthermore, OPA-1 deficient cells were shown to 
decrease oxidative phosphorylation (OXPHOS) (97, 98). In line with these previous 
studies, we observed a significant decrease of oxygen consumption rates (OCR) in LagA 
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treated HeLa cells, being consistent with a mitochondria-perturbing mode of action. 
Furthermore, the substantial decrease of basal respiration in LagA treated cells suggests 
that the natural product targets a pathway that is critical for oxidative phosphorylation. 
However, since the addition of Oligomycin, an ATP synthase inhibitor, generated a further 
decrease in OCR, it appears that LagA either has an incomplete effect or that a 
modulatory pathway is targeted. Additionally, FCCP, which uncouples oxygen 
consumption from ATP production, thereby raising OCR to a maximal value, caused an 
increase in OCR as well in LagA treated cells. Consistently, the spare respiratory capacity 
(the difference between basal and maximal respiration) remained constant upon LagA 
treatment. These findings further suggest that LagA does not directly target a protein that 
is necessary for the electron transport chain, as known inhibitors like Rotenone and 
Antimycin A produce a decrease in OCR that cannot be rescued by FCCP addition (99). 
Summarizing, these results indicate that LagA targets a component of a regulatory 
pathway of cellular metabolism, which could again be linked to mitochondrial dynamics. 
Moreover, altered mitochondrial dynamics also represent a key feature of KRAS 
dependent cellular transformation. Thereby, oncogenic KRAS stimulates mitochondrial 
fragmentation via ERK1/2 mediated phosphorylation of dynamin-related protein 1 (DRP1). 
Of note, fission is essential for RAS-driven tumor growth and along this line mitochondrial 
fission inhibition is discussed as a therapeutic approach for cancer treatment (52). These 
findings display that enhancing mitochondrial fission cannot uniformly be designated as 
anticancer strategy. For this reason, we additionally probed the effects of LagA on KRAS 
mutated (Panc 03.27 and Panc 10.05) and RAS-driven (BxPC3) pancreatic cancer cell 
lines, in order to transfer the LagA effects to another cellular model. Of note, LagA was 
able to inhibit cell growth and induce apoptosis in pancreatic cell types, with IC50 and EC50 
levels in the nanomolar range, similar to HeLa cells. This provides evidence that the 
cytotoxic effect of LagA is independent from the state of mitochondrial dynamics in cells. 
Regarding the molecular machinery of mitochondrial dynamics, LagA treatment did not 
deregulate the mitochondrial fusion protein Mfn-1, as it was shown in HeLa cells. Given 
the fact that KRAS- driven tumors rely on DRP1, we additionally investigated this 
mitochondrial fission regulator. However, LagA did not induce any alterations in the total 
form, but enhanced the phosphorylation at Ser637 selectively in the KRAS mutated cell 
line Panc 03.27. As this phosphorylation is linked to inhibition of fission, this most likely 
represents a feedback mechanism in response to LagA. Furthermore, only the long 
isoform of OPA-1 (L-OPA-1) decreased in pancreatic cell lines, whereas the protein levels 
of the short isoform (S-OPA-1) remained stable. Of note, the L-OPA-1 proteolytic 
cleavage is an important mechanism that regulates mitochondrial fission and fusion. 
Balanced formation of L- and S-OPA-1 preserves a tubular network of mitochondria. 
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Different stimuli can induce the cleavage of L-OPA-1, causing the accumulation of S-OPA-
1, which accelerates mitochondrial network fragmentation (100, 101). The reduction of L-
OPA-1 in LagA treated cells can be attributed to the observed fragmented mitochondrial 
phenotype. However, these data also reveal that none of the investigated fission / fusion 
regulators is affected directly by LagA, but suggest that a protein that is critical for 
mitochondrial dynamics is targeted. 
In summary, promoting mitochondrial fragmentation can be considered as anticancer 
strategy, highlighting LagA as a promising drug lead. Moreover, the differential effects of 
LagA on the molecular machinery of mitochondrial dynamics in different cell types 
highlight the complexity of this pathway. Importantly, these findings emphasize the need 
to characterize the exact molecular mode of action of LagA in order to use the natural 
product as molecular probe to investigate this cancer related pathway.  
6.1.2 Potential of Lagunamide A to trigger apoptotic cell death 
Mitochondria play a pivotal role in apoptotic cell death signaling. The mitochondrial outer 
membrane permeabilization (MOMP) of mitochondria during apoptosis results in 
cytochrome C release and activation of downstream caspases that execute apoptosis 
(102). MOMP is controlled by members of the Bcl-2 family of proteins. In this context, 
resistance to apoptotic stimuli and overexpression of anti-apoptotic Bcl-2 proteins are 
commonly seen characteristics in cancer (48). Of note, LagA markedly downregulated the 
anti-apoptotic Bcl-2 family members Bcl-2, Bcl-xl and Mcl-1 in different cancer cell lines 
and induced apoptotic cell death at nanomolar concentrations in all tested cell lines. 
Another protein that is crucial for mitochondrial apoptosis regulation is OPA-1. As key 
regulator of the mitochondrial cristae shape, OPA-1 plays a role in the process of cristae 
remodeling during apoptosis (103). Cristae remodeling is required to mobilize 
cytochrome c from the cristae space to the intermembrane space, where it is released 
across the outer mitochondrial membrane upon permeabilization (47). Sato et al. showed 
that the natural compound Aurilide induces apoptotic cell death by targeting the OPA-1 
dependent cristae remodeling and thereby substantiated the key role of OPA-1 in 
apoptosis regulation (70). Of note, the OPA-1 protein is also deregulated upon LagA 
treatment and more strikingly, mitochondrial cristae were found to be extremely enlarged 
in LagA treated cells. Keeping this in mind, it is likely that the OPA-1 dependent cristae 
remodeling may also contribute to LagA induced mitochondrial apoptosis.  
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Very importantly, small molecules like LagA that can selectively target mitochondria and 
activate the apoptotic cascade represent a directed approach in cancer therapy. 
Commonly used anticancer drugs mostly target signalling events upstream of the 
mitochondrial cell death machinery, for example by stabilizing p53. Such upstream 
pathways are often deregulated in human cancer, which in consequence often become 
resistant to conventional therapeutics (104, 105). Hence, compounds like LagA that 
directly target mitochondria may circumvent such resistance mechanisms and develop 
into promising treatment options for resistant forms of cancer. 
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8. Appendix 
8.1 Supplementary Figure 
 
Fig. S1 Thermal response curves of potential hits identified in thermal proteome profiling 
experiment. Thermal response curves for proteins passing all filtering thresholds when treating 
cells with 1 µM VioA (orange) compared to DMSO controls (grey). Melting points and melting curve 
fitting was carried out and data visualized using the TPP R package (60) and GraphPad Prism 8. 
CEP170 met all significance criteria in one replicate but was just outside the threshold for 
significance in the other. Experiment was performed by Volker Kirsch in the laboratory of Prof. Dr. 
Stephan Sieber (TU Munich, Germany). 
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8.2 Supplementary Tables 
Table S1: Calculated p-value, slope and curve fit for protein targets of vioprolide A in Jurkat 
cells as elucidated by in situ thermal proteome profiling. Proteins listed met all filter 
criteria.(60) CEP170 met all significance criteria in one replicate but was just outside the threshold 
for significance in the other. Data evaluation was performed by Volker Kirsch (laboratory of Prof. 
Dr. Stephan Sieber, TU Munich, Germany). 
Tm shift 
repl 1/2 
[°C] 
p-value adj. 
repl 1/2 
R
2
 curve fit 
(VioA1/DMSO1/
VioA2/DMSO2) 
Min. slope VioA 
vs DMSO repl. 
1/2 
Gene Protein 
6.61/8.85 6.5E-07/9.32E-
14 
0.81/0.94/0.84/0.
95 
-0.10/-0.10 NOP14 Nucleolar protein 14 
5.39/4.89 5.18E-
03/2.91E-02 
0.99/0.99/0.95/0.
99 
-0.08/--0.09 U2SURP U2 snRNP-
associated SURP 
motif-containing 
protein 
3.13/5.55 3.13E-
01/4.00E-05 
0.98/0.99/0.99/0.
99 
-0.09/-0.11 CEP170 Centrosomal protein 
of 170 kDa 
1.96/4.31 4.93E-
02/3.48E-03 
0.99/0.98/0.99/1.
00 
-0.18/-0.13 CDKN2AIP CDKN2A-interacting 
protein 
2.79/3.82 6.63E-03/1.2E-
03 
0.82/0.96/0.99/0.
84 
-1.29/-0.14 POLR3A DNA-directed RNA 
polymerase subunit 
-3.70/-2.00 3.32E-
02/1.55E-01 
0.99/0.98/0.96/1.
00 
-0.13/-0.19 RGS14 Regulator of G-
protein signaling 14 
 
-3.27/-3.53 8.03E-
02/8.61E-02 
0.99/0.93/0.92/0.
98 
-0.12/-0.09 SNX8 Sorting nexin-8 
 
Table S2: Proteins enriched in MS-based co-IP experiments. Listed proteins were significantly 
enriched in NOP14 antibody treated Jurkat cells in comparison to isotype control treated cells. 
Experiment was performed by Volker Kirsch in the laboratory of Prof. Dr. Stephan Sieber (TU 
Munich, Germany). 
log2 
enrichment 
-log10 (t-test p-
value) 
Gene Protein 
8.99 7.06 TFG Protein TFG; Tyrosine-protein kinase 
receptor 
8.06 5.53 SNAP29 Synaptosomal-associated protein 29 
7.12 6.76 NANS Sialic acid synthase 
6.75 5.46 NOP14 Nucleolar protein 14 
6.30 5.18 NOC4L Nucleolar complex protein 4 homolog 
5.13 5.32 DECR 2,4-dienoyl-CoA reductase, mitochondrial 
4.41 4.82 MTCL1 Microtubule cross-linking factor 1 
4.21 3.88 DTWD2 DTW domain-containing protein 2 
4.16 4.05 NACC1 Nucleus accumbens-associated protein 1 
3.70 4.86 IPO5 Importin-5 
3.45 3.82 SEPT6 Septin 6 
3.44 5.18 SEPT7 Septin 7 
3.32 5.76 TPR Nucleoprotein TPR 
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3.27 3.51 CIZ1 Cip1-interacting zinc finger protein 
3.27 3.11 GFPT1 Glutamine-fructose-6-phosphate 
aminotransferase 1 
3.12 4.68 PRKCA Protein kinase C alpha type 
3.10 4.72 SEPT2 Septin 2 
3.06 1.57 SUB1 Activated RNA polymerase II 
transcriptional coactivator p15 
2.98 3.53 HNRNPA2B1;HNR
PA2B1 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
2.75 4.00 NAPA Alpha-soluble NSF attachment protein 
2.69 3.27 IST1 IST1 homolog 
2.61 2.03 PPP2R1A Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha isoform 
2.48 4.89 EMG1 Ribosomal RNA small subunit 
methyltransferase NEP1 
2.28 3.39 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 
2.24 1.95 PPA1 Inorganic pyrophosphatase 
2.20 4.17 ATAD3A/B ATPase family AAA domain-containing 
protein 3A/B 
2.11 2.68 EEF1D Elongation factor 1-delta 
2.01 1.66 PCBP2 Poly(rC)-binding protein 2 
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8.3 Abbreviations 
5-FU ................................................................................................................... 5-Fluorouracil 
ActD .................................................................................................................. Actinomycin D 
ALL .......................................................................................... Acute lymphoblastic leukemia 
AML ................................................................................................... Acute myeloid leukemia 
ANOVA .................................................................................................... Analysis of variance 
AntA ...................................................................................................................... Antimycin A 
ATP .................................................................................................... Adenosine triphosphate 
BAK ........................................................................................... Bcl-2 homologous antagonist 
BAX ................................................................................................ Bcl-2 associated X protein 
Bcl-2 ........................................................................................................... B-cell lymphoma 2 
Bcl-xL .......................................................................................... B-cell lymphoma extra large 
BSA ...................................................................................................... Bovine serum albumin 
CASP3 .................................................................................................................... Caspase-3 
CASP8 .................................................................................................................... Caspase-8 
CIM .................................................................................................... Cell invasion/ migration 
CTB ..................................................................................................................... Cell titer blue 
Ctrl ................................................................................................................................ Control 
DMEM ........................................................................... Dulbecco's modified Eagle's Medium 
DMSO .......................................................................................................... Dimethylsulfoxide 
DNA .................................................................................................... Desoxyribonucleic acid 
Doxo ..................................................................................................................... Doxorubicin 
DRP1 ............................................................................................. Dynamin-related protein 1 
DSSO................................................................................................. Disuccinimidyl sulfoxide 
DTT ...................................................................................................................... Dithiothreitol 
EC₅₀ .............................................................................. Half-maximal effective concentration 
ECL ......................................................................................... Enhanced chemiluminescence 
EDTA .................................................................................... Ethylenediaminetetraacetic acid 
Em .............................................................................................................................Emission 
EMG1............................................... Ribosomal RNA small subunit methyltransferase Nep1 
ERK .............................................................................. Extracellular-signal regulated kinase 
Ex ..............................................................................................................................Excitation 
FACS ............................................................................... Fluorescence activated cell sorting 
FCCP .............................................. Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
FCS ................................................................................................................ Fetal calf serum 
FDA .................................................................................... US Food and Drug Administration 
FSC ................................................................................................................. Forward scatter 
GTP .................................................................................................. Guanosine triphosphate 
HILIC............................................................... Hydrophilic interaction liquid chromatography 
HRP ................................................................................................... Horseradish peroxidase 
IC₅₀ ............................................................................... Half-maximal inhibitory concentration 
IMDM .......................................................................... Iscove's Modified Dulbecco's Medium 
IP ............................................................................................................ Immunoprecipitation 
JC-1 ................................................................ Tetraethylbenzimidazolylcarbocyanine iodide 
KRAS ............................................................................................... Kirsten rat sarcoma virus 
LagA ................................................................................................................. Lagunamide A 
LC-MS................................................................ Liquid chromatography–mass spectrometry 
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mAb ........................................................................................................ Monoclonal antibody 
Mcl-1 .................................................... Induced myeloid leukemia cell differentiation protein 
MeOH ....................................................................................................................... Methanol 
MOMP......................................................... Mitochondrial outer membrane permeabilization 
MYC .......................................................... Avian myelocytomatosis viral oncogene homolog 
NOC4L ...................................................................Nucleolar complex associated 4 homolog 
NOP14 ..................................................................................................... Nucleolar protein 14 
NOR ............................................................................................. Nucleolar organizing region 
NP-40..................................................................................................................... Octoxinol 9 
NSG mice ........................................................................................... NOD scid gamma mice 
OCR ................................................................................................ Oxygen consumption rate 
OMA1................................................................ Metalloendopeptidase OMA1, mitochondrial 
OMM ...................................................................................... Outer mitochondrial membrane 
OPA1 ...............................................................................................................Optic atrophy 1 
OXPHOS ....................................................................................... Oxidative phosphorylation 
P/S ...................................................................................................... Penicillin/ streptomycin 
PAA ..................................................................................................................Polyacrylamide 
PAGE ............................................................................... Polyacrylamide gel electrophoresis 
PARP ......................................................................................... Poly ADP ribose polymerase 
PBMC ............................................................................... Peripheral blood mononuclear cell 
PBS .................................................................................................. Phosphate bufferd saline 
PDX ................................................................................................. Patient derived xenograft 
PE ...................................................................................................................... Phycoerythrin 
PFA ............................................................................................................ Paraformaldehyde 
PGC1α ........................................... Peroxisome proliferator-activated receptor-γ coactivator 
Phb1 ...................................................................................................................... Prohibitin 1 
PI .................................................................................................................. Propidium iodide 
Pol I ............................................................................................................ RNA polymerase I 
Pol II ........................................................................................................... RNA polymerase II 
Pol III......................................................................................................... RNA polymerase III 
PVDF ................................................................................................ Polyvinylidene difluoride 
rDNA ................................................................................................................ ribosomal DNA 
RNA ............................................................................................................... Ribonucleic acid 
ROS ................................................................................................. Reactive oxygen species 
RPMI ..................................................................................... Roswell Park Memorial Institute 
rRNA ............................................................................................................. Ribosomal  RNA 
RT .............................................................................................................. Room temperature 
SDS ................................................................................................. Sodium dodecyl sulafate 
SEM ............................................................................................. Standard error of the mean 
siRNA.................................................................................................... Small interfering RNA 
SPG7 ...................................................................................................... Spastic paraplegia 7 
SSC ...................................................................................................................... Side scatter 
TBS-T ........................................................................................ Tris-buffered saline + Tween 
TCE ................................................................................................................ Trichloroethanol 
TEM .................................................................................. Transmission electron microscopy 
TPP ............................................................................................... Thermal proteome profiling 
U2SURP ............................................ U2 snRNP-associated SURP motif-containing protein 
ULA .......................................................................................................... Ulta low attachment 
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VioA ...................................................................................................................... Vioprolide A 
VioB ...................................................................................................................... Vioprolide B 
VioC ..................................................................................................................... Vioprolide C 
VioD ..................................................................................................................... Vioprolide D 
Δᴪm .................................................................................. Mitochondrial membrane potential 
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